S8158424B2	NNP	O
-	:	O
Primate	NNP	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
medium	NN	O
containing	VBG	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid	NN	O
and	CC	O
lithium	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
12/209,325	CD	O
filed	VBD	O
Sep.	NNP	O
12,	,	O
2008,	,	O
now	RB	O
abandoned	VBN	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/221,457,	,	O
filed	VBD	O
Sep.	NNP	O
8,	,	O
2005,	,	O
now	RB	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,449,334	CD	O
issued	VBD	O
Nov.	NNP	O
11,	,	O
2008,	,	O
which	WDT	O
claimed	VBD	O
priority	NN	O
from	IN	O
U.S.	NNP	O
provisional	JJ	O
patent	NN	O
application	NN	O
Ser.	.	O
No.	.	O
60/608,040	CD	O
filed	VBD	O
Sep.	NNP	O
8,	,	O
2004.	.	O
This	DT	O
application	NN	O
is	VBZ	O
also	RB	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
12/242,085	CD	O
filed	VBD	O
Sep.	NNP	O
30,	,	O
2008,	,	O
now	RB	O
abandoned	VBN	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/221,516	CD	O
filed	VBD	O
Sep.	NNP	O
8,	,	O
2005,	,	O
now	RB	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,442,548	CD	O
issued	VBN	O
Oct.	NNP	O
28,	,	O
2008,	,	O
which	WDT	O
claimed	VBD	O
priority	NN	O
from	IN	O
U.S.	NNP	O
provisional	JJ	O
patent	NN	O
application	NN	O
Ser.	.	O
Nos.	.	O
60/695,100	CD	O
filed	VBD	O
Jun.	.	O
29,	,	O
2005	CD	O
and	CC	O
60/608,040	CD	O
filed	VBD	O
Sep.	NNP	O
8,	,	O
2004.	.	O
Each	DT	O
of	IN	O
these	DT	O
applications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety.	.	O
STATEMENT	NNP	O
REGARDING	NNP	O
FEDERALLY	NNP	O
SPONSORED	NNP	O
RESEARCH	NNP	O
OR	NNP	O
DEVELOPMENT	NNP	O
Some	DT	O
of	IN	O
the	DT	O
work	NN	O
described	VBN	O
in	IN	O
this	DT	O
specification	NN	O
was	VBD	O
supported	VBN	O
by	IN	O
grants	NNS	O
from	IN	O
the	DT	O
U.S.	NNP	O
Government	NNP	O
and	CC	O
some	DT	O
was	VBD	O
not.	.	O
None	NN	O
of	IN	O
the	DT	O
work	NN	O
described	VBN	O
in	IN	O
this	DT	O
specification	NN	O
on	IN	O
the	DT	O
process	NN	O
of	IN	O
deriving	VBG	O
new	JJ	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
was	VBD	O
supported	VBN	O
by	IN	O
any	DT	O
grant	JJ	O
money	NN	O
from	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
government.	.	O
New	NNP	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
derivations	NNS	O
and	CC	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
exclusively	RB	O
at	IN	O
WiCell,	,	O
using	VBG	O
privately	RB	O
funded	VBN	O
WiCell	NNP	O
facilities,	,	O
equipment	NN	O
and	CC	O
personnel.	.	O
To	TO	O
the	DT	O
extent	NN	O
this	DT	O
invention	NN	O
was	VBD	O
made	VBN	O
with	IN	O
United	NNP	O
States	NNPS	O
government	NN	O
support,	,	O
the	DT	O
award	NN	O
was	VBD	O
provided	VBN	O
by:	:	O
NIH	NNP	O
R24-RR017721	NNP	O
and	CC	O
P20-GMO69981.	.	O
The	DT	O
United	NNP	O
States	NNPS	O
government	NN	O
has	VBZ	O
certain	JJ	O
rights	NNS	O
in	IN	O
this	DT	O
invention.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Primate	NNP	O
embryonic	JJ	O
stem	NN	O
(ES)	)	O
cells	NNS	O
and	CC	O
the	DT	O
recently-described	JJ	O
induced	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
(iPS)	)	O
(collectively,	,	O
“pluripotent	NNP	O
cells”)	)	O
can	MD	O
proliferate	VB	O
without	IN	O
limit	NN	O
and	CC	O
can	MD	O
differentiate	VB	O
into	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
embryonic	JJ	O
germ	NN	O
layers.	.	O
ES	NNP	O
cells	NNS	O
are	VBP	O
stem	JJ	O
cells	NNS	O
found	VBN	O
in	IN	O
or	CC	O
derived	VBN	O
from	IN	O
embryos.	.	O
ES	NNP	O
cells	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
differentiation	NN	O
into	IN	O
most,	,	O
if	IN	O
not	RB	O
all,	,	O
of	IN	O
the	DT	O
differentiated	VBN	O
cell	NN	O
types	NNS	O
of	IN	O
a	DT	O
mature	NN	O
body.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
iPS	JJ	O
cells	NNS	O
behave	VBP	O
in	IN	O
culture	NN	O
essentially	RB	O
the	DT	O
same	JJ	O
as	IN	O
ES	NNP	O
cells.	.	O
iPS	NN	O
cells	NNS	O
and	CC	O
ES	NNP	O
cells	NNS	O
express	VBP	O
one	CD	O
or	CC	O
more	JJR	O
pluripotent	JJ	O
cell-specific	JJ	O
marker,	,	O
such	JJ	O
as	IN	O
Oct-4,	,	O
SSEA-3,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
Tra	NNP	O
1-81,	,	O
and	CC	O
Nanog	NNP	O
Yu	NNP	B
et	RB	I
al.	.	I
Science,	,	I
Vol.	.	I
318.	CD	I
no.	.	I
5858,	,	I
pp.	.	I
1917-1920	CD	I
(2007),	,	I
(incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety)	)	O
Also,	,	O
recent	JJ	O
findings	NNS	O
of	IN	O
Chan,	,	O
suggest	VBP	O
that	IN	O
expression	NN	O
of	IN	O
Tra	NNP	O
1-60,	,	O
DNMT3B,	,	O
and	CC	O
REX1	NNP	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
positively	RB	O
identify	VB	O
fully	RB	O
reprogrammed	VBN	O
iPS	JJ	O
cells,	,	O
whereas	NNS	O
alkaline	VBP	O
phosphatase,	,	O
SSEA-4,	,	O
GDF3,	,	O
hTERT,	,	O
and	CC	O
NANOG	NNP	O
are	VBP	O
insufficient	JJ	O
as	IN	O
markers	NNS	O
of	IN	O
fully	RB	O
reprogrammed	VBN	O
iPS	JJ	O
cells.	.	O
Chan	NNP	B
et	RB	I
al.,	,	I
Nat.	.	I
Biotech.	.	I
27:1033-1037	CD	I
(2009),	,	I
(incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety).	.	O
Subsequent	JJ	O
references	NNS	O
herein	VBP	O
to	TO	O
primate	VB	O
or	CC	O
human	JJ	O
ES	NNP	O
cells	NNS	O
and	CC	O
the	DT	O
like	JJ	O
are	VBP	O
intended	VBN	O
to	TO	O
apply	VB	O
with	IN	O
equal	JJ	O
force	NN	O
to	TO	O
iPS	VB	O
cells.	.	O
Pluripotent	NN	O
cells	NNS	O
are	VBP	O
of	IN	O
high	JJ	O
interest	NN	O
to	TO	O
the	DT	O
research	NN	O
community	NN	O
and	CC	O
regenerative	JJ	O
industry	NN	O
because	IN	O
they	PRP	O
are	VBP	O
capable	JJ	O
of	IN	O
indefinite	JJ	O
proliferation	NN	O
in	IN	O
culture.	.	O
Thus,	,	O
at	IN	O
least	JJS	O
in	IN	O
principle,	,	O
pluripotent	NN	O
cells	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
supplying	VBG	O
cells	NNS	O
and	CC	O
tissues	NNS	O
for	IN	O
replacement	NN	O
of	IN	O
failing	VBG	O
or	CC	O
defective	JJ	O
human	JJ	O
tissue.	.	O
This	DT	O
is	VBZ	O
why	WRB	O
the	DT	O
existence	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
offers	VBZ	O
the	DT	O
potential	NN	O
of	IN	O
unlimited	JJ	O
amounts	NNS	O
of	IN	O
human	JJ	O
cells	NNS	O
and	CC	O
tissues	NNS	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
therapeutic	JJ	O
protocols	NNS	O
to	TO	O
assist	VB	O
in	IN	O
human	JJ	O
health.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
in	IN	O
the	DT	O
future	NN	O
that	WDT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
will	MD	O
be	VB	O
proliferated	VBN	O
and	CC	O
directed	VBN	O
to	TO	O
differentiate	VB	O
into	IN	O
specific	JJ	O
lineages	NNS	O
so	RB	O
as	IN	O
to	TO	O
develop	VB	O
differentiated	JJ	O
cells	NNS	O
or	CC	O
tissues	NNS	O
which	WDT	O
can	MD	O
be	VB	O
transplanted	VBN	O
into	IN	O
human	JJ	O
bodies	NNS	O
for	IN	O
therapeutic	JJ	O
purposes.	.	O
Human	NNP	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
and	CC	O
the	DT	O
differentiated	JJ	O
cells	NNS	O
that	WDT	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
them	PRP	O
are	VBP	O
also	RB	O
powerful	JJ	O
scientific	JJ	O
tools	NNS	O
for	IN	O
the	DT	O
study	NN	O
of	IN	O
human	JJ	O
cellular	JJ	O
and	CC	O
developmental	JJ	O
systems.	.	O
Specifically,	,	O
the	DT	O
basic	JJ	O
techniques	NNS	O
to	TO	O
create	VB	O
and	CC	O
culture	NN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
have	VBP	O
been	VBN	O
described.	.	O
The	DT	O
previously	RB	O
reported	VBN	O
techniques	NNS	O
do	VBP	O
work,	,	O
but	CC	O
there	EX	O
are	VBP	O
limitations	NNS	O
and	CC	O
drawbacks	NNS	O
to	TO	O
many	JJ	O
of	IN	O
the	DT	O
procedures	NNS	O
currently	RB	O
used	VBN	O
to	TO	O
culture	NN	O
human	JJ	O
ES	NNP	O
cells.	.	O
One	CD	O
limitation	NN	O
of	IN	O
particular	JJ	O
concern	NN	O
is	VBZ	O
that	IN	O
most	JJS	O
existing	VBG	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
have	VBP	O
been,	,	O
to	TO	O
one	CD	O
degree	NN	O
or	CC	O
another,	,	O
exposed	VBN	O
directly	RB	O
to	TO	O
mouse	VB	O
cells	NNS	O
or	CC	O
to	TO	O
a	DT	O
medium	NN	O
in	IN	O
which	WDT	O
mouse	NN	O
cells	NNS	O
have	VBP	O
been	VBN	O
previously	RB	O
cultured.	.	O
This	DT	O
is	VBZ	O
because	IN	O
the	DT	O
original	JJ	O
techniques	NNS	O
for	IN	O
generating	VBG	O
and	CC	O
culturing	VBG	O
human	JJ	O
ES	NNP	O
cells	NNS	O
required	VBD	O
using	VBG	O
mouse	NN	O
embryonic	JJ	O
fibroblast	NN	O
(MEF)	)	O
feeder	NN	O
cells	NNS	O
as	IN	O
a	DT	O
feeder	NN	O
layer	NN	O
on	IN	O
which	WDT	O
human	JJ	O
ES	NNP	O
cells	NNS	O
could	MD	O
be	VB	O
cultured.	.	O
The	DT	O
fibroblast	NN	O
feeder	NN	O
cells	NNS	O
act,	,	O
through	IN	O
some	DT	O
as	IN	O
yet	RB	O
incompletely	RB	O
understood	JJ	O
mechanism,	,	O
to	TO	O
encourage	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
to	TO	O
remain	VB	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state.	.	O
A	DT	O
by-product	NN	O
of	IN	O
such	JJ	O
techniques	NNS	O
is	VBZ	O
that	IN	O
some	DT	O
human	JJ	O
ES	NNP	O
cells	NNS	O
from	IN	O
existing	VBG	O
cell	NN	O
lines	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
exhibit	VB	O
the	DT	O
sialic	JJ	O
residue	JJ	O
Neu5Gc,	,	O
which	WDT	O
is	VBZ	O
not	RB	O
normally	RB	O
made	VBN	O
by	IN	O
human	JJ	O
cells	NNS	O
but	CC	O
is	VBZ	O
made	VBN	O
by	IN	O
murine	NN	O
cells,	,	O
and	CC	O
has	VBZ	O
received	VBN	O
much	JJ	O
attention	NN	O
in	IN	O
the	DT	O
press.	.	O
Later,	,	O
it	PRP	O
was	VBD	O
discovered	VBN	O
that	IN	O
the	DT	O
benefits	NNS	O
MEF	NNP	O
feeder	NN	O
cells	NNS	O
provide	VBP	O
to	TO	O
stem	VB	O
cells	NNS	O
grown	VBN	O
in	IN	O
culture	NN	O
could	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
exposing	VBG	O
stem	NN	O
cells	NNS	O
to	TO	O
“conditioned	VB	O
medium.”	NN	O
Conditioned	NNP	O
medium	NN	O
is	VBZ	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
medium	NN	O
in	IN	O
which	WDT	O
feeder	NN	O
cells,	,	O
such	JJ	O
as	IN	O
MEFs,	,	O
had	VBD	O
been	VBN	O
previously	RB	O
cultured.	.	O
In	IN	O
conditioned	JJ	O
medium,	,	O
either	CC	O
the	DT	O
feeder	NN	O
cells	NNS	O
impart	VBP	O
some	DT	O
factor	NN	O
to	TO	O
the	DT	O
medium	NN	O
or	CC	O
remove	VB	O
some	DT	O
factor	NN	O
from	IN	O
the	DT	O
medium,	,	O
which	WDT	O
allows	VBZ	O
stem	NN	O
cells	NNS	O
to	TO	O
be	VB	O
cultured	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state.	.	O
Although	IN	O
the	DT	O
mechanisms	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
conditioned	JJ	O
medium	NN	O
have	VBP	O
not	RB	O
been	VBN	O
fully	RB	O
elucidated,	,	O
the	DT	O
result	NN	O
is	VBZ	O
that	IN	O
conditioned	JJ	O
medium	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
with	IN	O
minimal	JJ	O
differentiation.	.	O
Both	DT	O
direct	JJ	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
murine	NN	O
feeder	NN	O
cells	NNS	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
conditioned	JJ	O
media	NNS	O
raise	VBP	O
the	DT	O
concern	NN	O
that	WDT	O
one	CD	O
or	CC	O
more	JJR	O
agents,	,	O
such	JJ	O
as	IN	O
a	DT	O
virus,	,	O
could	MD	O
be	VB	O
transmitted	VBN	O
from	IN	O
the	DT	O
mouse	NN	O
cells	NNS	O
to	TO	O
the	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells.	.	O
If	IN	O
one	CD	O
of	IN	O
the	DT	O
applied	JJ	O
objectives	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
is	VBZ	O
to	TO	O
create	VB	O
cells	NNS	O
and	CC	O
tissues	NNS	O
which	WDT	O
can	MD	O
ultimately	RB	O
be	VB	O
transplanted	VBN	O
into	IN	O
a	DT	O
human	JJ	O
body,	,	O
it	PRP	O
is	VBZ	O
highly	RB	O
desirable	JJ	O
to	TO	O
generate	VB	O
stem	NN	O
cells	NNS	O
that	WDT	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
cells	NNS	O
of	IN	O
another	DT	O
species	NNS	O
or	CC	O
to	TO	O
media	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
culture	NN	O
cells	NNS	O
of	IN	O
another	DT	O
species.	.	O
Accordingly,	,	O
defining	VBG	O
a	DT	O
culture	NN	O
condition,	,	O
which	WDT	O
will	MD	O
permit	VB	O
the	DT	O
proliferation	NN	O
and	CC	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
a	DT	O
fibroblast	NN	O
feeder	NN	O
layer,	,	O
is	VBZ	O
of	IN	O
great	JJ	O
interest	NN	O
in	IN	O
the	DT	O
continued	JJ	O
development	NN	O
of	IN	O
techniques	NNS	O
for	IN	O
the	DT	O
long	JJ	O
term	NN	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells.	.	O
Several	JJ	O
medium	NN	O
formulations	NNS	O
will	MD	O
permit	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
to	TO	O
remain	VB	O
undifferentiated	JJ	O
for	IN	O
some	DT	O
time,	,	O
but	CC	O
the	DT	O
undifferentiated	JJ	O
state	NN	O
often	RB	O
fails	VBZ	O
to	TO	O
maintain	VB	O
itself.	.	O
The	DT	O
inventors	NNS	O
here	RB	O
have	VBP	O
found	VBN	O
several	JJ	O
medium	NN	O
formulations	NNS	O
that	WDT	O
permit	VBP	O
the	DT	O
cultivation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
for	IN	O
one	CD	O
or	CC	O
two	CD	O
passages	NNS	O
without	IN	O
severe	JJ	O
differentiation,	,	O
but	CC	O
then	RB	O
the	DT	O
cells	NNS	O
differentiate	VBP	O
rapidly	RB	O
upon	IN	O
subsequent	JJ	O
passages.	.	O
In	IN	O
particular,	,	O
“passage”	EX	O
is	VBZ	O
defined	JJ	O
herein	RB	O
as	IN	O
the	DT	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
from	IN	O
an	DT	O
initial	JJ	O
seed	NN	O
culture	NN	O
in	IN	O
a	DT	O
culture	NN	O
vessel	NN	O
to	TO	O
confluence	VB	O
in	IN	O
the	DT	O
same	JJ	O
culture	NN	O
vessel.	.	O
The	DT	O
inventors	NNS	O
have	VBP	O
come	VBN	O
to	TO	O
believe	VB	O
that	IN	O
in	IN	O
order	NN	O
for	IN	O
a	DT	O
culture	NN	O
medium	NN	O
to	TO	O
truly	VB	O
support	VB	O
the	DT	O
indefinite	JJ	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
differentiation	NN	O
and	CC	O
without	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
medium	NN	O
that	WDT	O
is	VBZ	O
conditioned	VBN	O
therewith,	,	O
the	DT	O
medium	NN	O
must	MD	O
be	VB	O
capable	JJ	O
of	IN	O
supporting	VBG	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
a	DT	O
substantially	RB	O
uniform	JJ	O
and	CC	O
undifferentiated	JJ	O
state	NN	O
for	IN	O
at	IN	O
least	JJS	O
five	CD	O
passages.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
important	JJ	O
that	IN	O
the	DT	O
cultures	NNS	O
remain	VBP	O
relatively	RB	O
homogenous	JJ	O
and	CC	O
undifferentiated	JJ	O
throughout	IN	O
the	DT	O
culture	NN	O
period	NN	O
and	CC	O
retain	VB	O
all	DT	O
of	IN	O
the	DT	O
important	JJ	O
characteristics	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells.	.	O
A	DT	O
characteristic	JJ	O
trait	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
is	VBZ	O
that,	,	O
if	IN	O
conditions	NNS	O
are	VBP	O
less	JJR	O
than	IN	O
ideal,	,	O
the	DT	O
cells	NNS	O
have	VBP	O
a	DT	O
tendency	NN	O
to	TO	O
differentiate.	.	O
It	PRP	O
is	VBZ	O
easy	JJ	O
to	TO	O
induce	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
to	TO	O
differentiate,	,	O
while	IN	O
it	PRP	O
is	VBZ	O
challenging	VBG	O
to	TO	O
maintain	VB	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
in	IN	O
culture.	.	O
Most	JJS	O
culture	NN	O
conditions	NNS	O
will	MD	O
result	VB	O
in	IN	O
some	DT	O
level	NN	O
of	IN	O
unwanted	JJ	O
differentiation,	,	O
particularly	RB	O
around	IN	O
the	DT	O
periphery	NN	O
of	IN	O
the	DT	O
growing	VBG	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
colony.	.	O
While	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
with	IN	O
some	DT	O
degree	NN	O
of	IN	O
unwanted	JJ	O
differentiation,	,	O
the	DT	O
objective	NN	O
is	VBZ	O
to	TO	O
define	VB	O
a	DT	O
culture	NN	O
condition	NN	O
that	WDT	O
permits	VBZ	O
the	DT	O
culture	NN	O
to	TO	O
remain	VB	O
as	RB	O
undifferentiated	JJ	O
as	IN	O
possible,	,	O
i.e.,	,	O
with	IN	O
as	IN	O
few	JJ	O
differentiated	JJ	O
cells	NNS	O
as	IN	O
possible.	.	O
To	TO	O
achieve	VB	O
this	DT	O
objective,	,	O
the	DT	O
inventors	NNS	O
have	VBP	O
used	VBN	O
particularly	RB	O
stringent	JJ	O
standards	NNS	O
to	TO	O
define	VB	O
conditions	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
indefinite	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures,	,	O
as	IN	O
described	VBN	O
below.	.	O
The	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
morphological	JJ	O
characteristics.	.	O
Undifferentiated	JJ	O
stem	NN	O
cells	NNS	O
have	VBP	O
a	DT	O
characteristic	JJ	O
morphology,	,	O
i.e.,	,	O
small	JJ	O
and	CC	O
compact	JJ	O
cells	NNS	O
with	IN	O
clearly	RB	O
defined	VBN	O
cell	NN	O
borders,	,	O
a	DT	O
morphology	NN	O
which	WDT	O
can	MD	O
be	VB	O
easily	RB	O
seen	VBN	O
by	IN	O
examination	NN	O
of	IN	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
under	IN	O
a	DT	O
microscope.	.	O
By	IN	O
contrast,	,	O
cells	NNS	O
which	WDT	O
have	VBP	O
differentiated	VBN	O
appear	JJ	O
larger	JJR	O
and	CC	O
more	RBR	O
diffuse	NN	O
with	IN	O
indistinct	JJ	O
cell	NN	O
borders.	.	O
While	IN	O
some	DT	O
differentiated	JJ	O
cells	NNS	O
can,	,	O
and	CC	O
normally	RB	O
do,	,	O
appear	VB	O
at	IN	O
the	DT	O
margin	NN	O
of	IN	O
colonies	NNS	O
of	IN	O
undifferentiated	JJ	O
cells,	,	O
the	DT	O
optimal	JJ	O
stem	NN	O
cell	NN	O
culture	NN	O
is	VBZ	O
one	CD	O
that	WDT	O
proliferates	VBZ	O
in	IN	O
the	DT	O
culture	NN	O
vessel	NN	O
with	IN	O
only	JJ	O
minimal	JJ	O
numbers	NNS	O
of	IN	O
cells	NNS	O
at	IN	O
the	DT	O
periphery	NN	O
of	IN	O
the	DT	O
culture	NN	O
appearing	VBG	O
to	TO	O
be	VB	O
differentiated.	.	O
With	IN	O
experience,	,	O
stem	NN	O
cell	NN	O
researchers	NNS	O
can	MD	O
judge	VB	O
the	DT	O
status	NN	O
of	IN	O
differentiation	NN	O
and	CC	O
health	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
visually	RB	O
with	IN	O
good	JJ	O
accuracy.	.	O
In	IN	O
addition	NN	O
to	TO	O
morphological	JJ	O
characteristics,	,	O
biochemical	JJ	O
cell	NN	O
markers	NNS	O
are	VBP	O
routinely	RB	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
status	NN	O
of	IN	O
ES	NNP	O
cells	NNS	O
as	IN	O
undifferentiated.	.	O
For	IN	O
example,	,	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
is	VBZ	O
regarded	VBN	O
as	IN	O
the	DT	O
most	RBS	O
reliable	JJ	O
marker	NN	O
of	IN	O
undifferentiated	JJ	O
status	NN	O
for	IN	O
ES	NNP	O
cells.	.	O
Oct-4	NNP	O
is	VBZ	O
also	RB	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
markers	NNS	O
lost	VBN	O
as	IN	O
undifferentiated	JJ	O
cells	NNS	O
begin	VBP	O
to	TO	O
differentiate.	.	O
Other	JJ	O
biochemical	JJ	O
markers	NNS	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
status	NN	O
of	IN	O
undifferentiated	JJ	O
primate	NN	O
ES	NNP	O
cells	NNS	O
and	CC	O
human	JJ	O
ES	NNP	O
cells	NNS	O
include:	:	O
SSEA-3,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
and	CC	O
alkaline	JJ	O
phosphatase,	,	O
but	CC	O
not	RB	O
SSEA-1.	.	O
In	IN	O
contrast,	,	O
undifferentiated	JJ	O
mouse	NN	O
ES	NNP	O
cells	NNS	O
express	JJ	O
SSEA-1,	,	O
but	CC	O
not	RB	O
SSEA-3,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
and	CC	O
Tra	NNP	O
1-81.	.	O
Tra	NNP	O
1-60,	,	O
and	CC	O
Tra	NNP	O
1-81	NNS	O
are	VBP	O
antibodies	NNS	O
to	TO	O
extracellular	VB	O
matrix	NN	O
molecules	NNS	O
synthesized	VBN	O
by	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
which	WDT	O
are	VBP	O
also	RB	O
markers	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cells.	.	O
Further,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
Nanog	NNP	O
is	VBZ	O
a	DT	O
transcription	NN	O
factor	NN	O
that	WDT	O
is	VBZ	O
essential	JJ	O
for	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
pluripotency	NN	O
and	CC	O
self	NN	O
renewal	NN	O
in	IN	O
pluripotent	JJ	O
stem	NN	O
cells.	.	O
In	IN	O
addition	NN	O
to	TO	O
stringent	JJ	O
standards	NNS	O
required	VBN	O
for	IN	O
conditions	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
indefinite	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures,	,	O
the	DT	O
conditions	NNS	O
needed	VBN	O
for	IN	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
is	VBZ	O
an	DT	O
even	RB	O
more	RBR	O
stringent.	.	O
This	DT	O
is	VBZ	O
because	IN	O
some	DT	O
culture	NN	O
conditions	NNS	O
which	WDT	O
support	VBP	O
the	DT	O
expansion	NN	O
and	CC	O
growth	NN	O
of	IN	O
existing	VBG	O
stem	NN	O
cells	NNS	O
lines	NNS	O
have	VBP	O
not	RB	O
proven	VBN	O
sufficient	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines.	.	O
It	PRP	O
appears	VBZ	O
that	IN	O
the	DT	O
capacity	NN	O
to	TO	O
support	VB	O
the	DT	O
initiation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
stem	NN	O
cells	NNS	O
is	VBZ	O
a	DT	O
capacity	NN	O
that	IN	O
not	RB	O
all	DT	O
stem	NN	O
cell	JJ	O
culture	NN	O
conditions	NNS	O
feature.	.	O
Accordingly,	,	O
media	NNS	O
to	TO	O
support	VB	O
initiation,	,	O
proliferation	NN	O
and	CC	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
primate	NN	O
stem	NN	O
cells	NNS	O
are	VBP	O
desired	VBN	O
by	IN	O
the	DT	O
stem	NN	O
cell	NN	O
industry.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
In	IN	O
a	DT	O
first	JJ	O
aspect,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
summarized	VBN	O
as	IN	O
a	DT	O
defined	JJ	O
medium	NN	O
for	IN	O
culturing	VBG	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
including	VBG	O
ES	NNP	O
cells	NNS	O
and	CC	O
iPS	JJ	O
cells.	.	O
The	DT	O
medium	NN	O
is	VBZ	O
a	DT	O
serum-free,	,	O
animal	JJ	O
product-free	JJ	O
medium	NN	O
that	WDT	O
supports	VBZ	O
the	DT	O
derivation	NN	O
and	CC	O
long-term	JJ	O
feeder-independent	JJ	O
culture	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells.	.	O
The	DT	O
defined	JJ	O
medium	NN	O
includes	VBZ	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
lipids,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
(FGF),	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
gamma	NN	O
amino	NN	O
butyric	JJ	O
acid	NN	O
(GABA),	,	O
pipecolic	JJ	O
acid	NN	O
(PA),	,	O
and	CC	O
lithium	NN	O
(Li),	,	O
all	DT	O
in	IN	O
sufficient	JJ	O
amount	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages.	.	O
Optionally,	,	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
(TGFβ)	)	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
defined	JJ	O
medium	NN	O
in	IN	O
sufficient	JJ	O
amount	NN	O
so	RB	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
indefinitely	RB	O
in	IN	O
an	DT	O
undifferentiated,	,	O
pluripotent	JJ	O
and	CC	O
proliferative	JJ	O
state	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
culturing	VBG	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
with	IN	O
a	DT	O
defined	JJ	O
medium	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
the	DT	O
step	NN	O
of	IN	O
culturing	VBG	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
lipids,	,	O
a	DT	O
FGF,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
all	DT	O
in	IN	O
sufficient	JJ	O
amount	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
an	DT	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
high	JJ	O
levels	NNS	O
of	IN	O
a	DT	O
FGF,	,	O
lipids	NNS	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
so	IN	O
that	IN	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
indefinitely	RB	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
the	DT	O
creation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
new	JJ	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines,	,	O
which	WDT	O
can	MD	O
be	VB	O
cultured	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state,	,	O
and	CC	O
which	WDT	O
have	VBP	O
not	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
animal	JJ	O
products,	,	O
feeder	NN	O
cells,	,	O
or	CC	O
conditioned	VBD	O
medium.	.	O
Also	RB	O
disclosed	VBN	O
are	VBP	O
defined	VBN	O
long	JJ	O
term	NN	O
culture	NN	O
conditions	NNS	O
for	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
that	WDT	O
avoid	VBP	O
exposure	NN	O
to	TO	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
animal	JJ	O
cells	NNS	O
or	CC	O
proteins	NNS	O
in	IN	O
which	WDT	O
stem	NN	O
cells	NNS	O
are	VBP	O
often	RB	O
cultured.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
culturing	VBG	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media,	,	O
the	DT	O
medium	NN	O
including	VBG	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA	NNP	O
and	CC	O
Li,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages.	.	O
A	DT	O
suitable	JJ	O
matrix	NN	O
is	VBZ	O
a	DT	O
solubilized	JJ	O
basement	NN	O
membrane	NN	O
preparation	NN	O
extracted	VBD	O
from	IN	O
the	DT	O
Engelbreth-Holm-Swarm	NNP	O
mouse	NN	O
sarcoma	NN	O
(Matrigel™)	)	O
or	CC	O
a	DT	O
matrix	NN	O
that	WDT	O
includes	VBZ	O
human	JJ	O
matrix	NN	O
proteins	NNS	O
collagen	VBP	O
IV	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
fibronectin,	,	O
laminin	NN	O
and	CC	O
vitronectin.	.	O
Preferably,	,	O
collagen	NN	O
IV,	,	O
fibronectin,	,	O
laminin	NN	O
and	CC	O
vitronectin	NN	O
are	VBP	O
all	DT	O
included	VBN	O
in	IN	O
the	DT	O
matrix.	.	O
Optionally,	,	O
TGFβ	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
defined	JJ	O
medium.	.	O
The	DT	O
defined	JJ	O
growth	NN	O
factors,	,	O
GABA,	,	O
PA	NNP	O
and	CC	O
Li,	,	O
are	VBP	O
added	VBN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state,	,	O
wherein	NN	O
at	IN	O
least	JJS	O
90%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
having	VBG	O
in	IN	O
a	DT	O
culture	NN	O
vessel:	:	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells;	:	O
a	DT	O
matrix,	,	O
on	IN	O
which	WDT	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
grow;	:	O
and	CC	O
a	DT	O
culture	NN	O
medium,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
comprises	VBZ	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect,	,	O
the	DT	O
matrix	NN	O
includes	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
collagen	NN	O
IV,	,	O
fibronectin,	,	O
laminin,	,	O
and	CC	O
vitronectin.	.	O
Preferably,	,	O
at	IN	O
least	JJS	O
two,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
three,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
all	DT	O
four	CD	O
human	JJ	O
matrix	NN	O
proteins	NNS	O
are	VBP	O
present.	.	O
The	DT	O
culture	NN	O
medium	NN	O
includes	VBZ	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF,	,	O
GABA,	,	O
PA,	,	O
Li	NNP	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state,	,	O
so	IN	O
that	DT	O
at	IN	O
least	JJS	O
90%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells.	.	O
Preferably,	,	O
the	DT	O
medium	NN	O
also	RB	O
is	VBZ	O
free	JJ	O
of	IN	O
products	NNS	O
from	IN	O
non-human	JJ	O
animals.	.	O
In	IN	O
another	DT	O
aspect,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
medium	NN	O
comprising	NN	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
and	CC	O
optionally	RB	O
TGFβ	NNP	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
wherein	NN	O
at	IN	O
least	JJS	O
90%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages.	.	O
Suitably,	,	O
the	DT	O
FGF	NNP	O
concentration	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
between	IN	O
40	CD	O
ng/ml	NNS	O
and	CC	O
100	CD	O
ng/ml.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect,	,	O
when	WRB	O
beta-mercaptoethanol	NN	O
was	VBD	O
either	RB	O
omitted	VBN	O
or	CC	O
added	VBN	O
at	IN	O
a	DT	O
concentration	NN	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
in	IN	O
the	DT	O
culture	NN	O
medium,	,	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10%	NN	O
compared	VBN	O
to	TO	O
pluripotent	VB	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium,	,	O
having	VBG	O
a	DT	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
concentration	NN	O
of	IN	O
beta-mercaptoethanol.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
initiating	VBG	O
a	DT	O
cultured	JJ	O
line	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium,	,	O
the	DT	O
method	NN	O
including	VBG	O
the	DT	O
step	NN	O
of	IN	O
plating	VBG	O
cells	NNS	O
from	IN	O
a	DT	O
blastocyst	NN	O
onto	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
originate	VB	O
and	CC	O
maintain	VB	O
a	DT	O
new	JJ	O
proliferating	VBG	O
stem	NN	O
cell	NN	O
line	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state.	.	O
Another	DT	O
aspect	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
culturing	VBG	O
new	JJ	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
including	VBG	O
the	DT	O
steps	NNS	O
of	IN	O
culturing	VBG	O
stem	NN	O
cells	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
isolated	VBN	O
from	IN	O
the	DT	O
inner	NN	O
cell	NN	O
mass	NN	O
of	IN	O
an	DT	O
embryo	NN	O
in	IN	O
the	DT	O
blastocyst	NN	O
stage	NN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
the	DT	O
culturing	VBG	O
step	NN	O
being	VBG	O
conducted	VBN	O
on	IN	O
a	DT	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
comprising	VBG	O
collagen	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
protein	NN	O
selected	VBN	O
from	IN	O
fibronectin,	,	O
vitronectin,	,	O
and	CC	O
laminin,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells;	:	O
and	CC	O
serially	RB	O
expanding	VBG	O
the	DT	O
cells	NNS	O
which	WDT	O
proliferate	VBP	O
on	IN	O
the	DT	O
medium.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
having	VBG	O
(i)	)	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
that	WDT	O
comprises	VBZ	O
a	DT	O
humanized	JJ	O
matrix	NN	O
made	VBN	O
from	IN	O
human	JJ	O
collagen	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
human	JJ	O
protein	NN	O
selected	VBN	O
from	IN	O
fibronectin,	,	O
vitronectin	NN	O
and	CC	O
laminin	NN	O
and	CC	O
(ii)	)	O
a	DT	O
cell	NN	O
culture	NN	O
medium	NN	O
that	WDT	O
comprises	VBZ	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
FGF	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect,	,	O
the	DT	O
matrix	NN	O
includes	VBZ	O
collagen,	,	O
fibronectin,	,	O
vitronectin	NN	O
and	CC	O
laminin.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
GABA,	,	O
PA,	,	O
and	CC	O
Li.	.	O
In	IN	O
this	DT	O
aspect,	,	O
the	DT	O
cultured	JJ	O
pluripotent	NN	O
cells	NNS	O
are	VBP	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cells,	,	O
which	WDT	O
do	VBP	O
not	RB	O
exhibit	VB	O
the	DT	O
sialic	JJ	O
acid	NN	O
Neu5Gc	NNP	O
and	CC	O
the	DT	O
medium	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
maintaining	VBG	O
the	DT	O
cells	NNS	O
through	IN	O
over	IN	O
twenty	JJ	O
passages	NNS	O
in	IN	O
culture	NN	O
while	IN	O
the	DT	O
cells	NNS	O
remain	VBP	O
undifferentiated,	,	O
maintain	JJ	O
pluripotency,	,	O
and	CC	O
maintain	VBP	O
stable	JJ	O
karyotype.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
cell	NN	O
culture	NN	O
medium	NN	O
having	VBG	O
albumin,	,	O
minerals,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
a	DT	O
FGF,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
and	CC	O
at	IN	O
least	JJS	O
two	CD	O
members	NNS	O
selected	VBN	O
from	IN	O
GABA,	,	O
PA,	,	O
and	CC	O
Li	NNP	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
that	IN	O
with	IN	O
the	DT	O
medium	NN	O
and	CC	O
culture	NN	O
system	NN	O
described	VBD	O
here,	,	O
one	CD	O
can	MD	O
establish	VB	O
and	CC	O
maintain	VB	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
70%,	,	O
at	IN	O
least	JJS	O
80%,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
85%,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
at	IN	O
least	JJS	O
90%	NN	O
undifferentiated	JJ	O
stem	NN	O
cells.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
method	NN	O
of	IN	O
increasing	VBG	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
by	IN	O
culturing	VBG	O
the	DT	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media,	,	O
the	DT	O
medium	NN	O
comprising	NN	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid,	,	O
and	CC	O
lithium	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
and	CC	O
such	JJ	O
that	IN	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
pluripotent	NN	O
cells	NNS	O
is	VBZ	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10%	NN	O
compared	VBN	O
to	TO	O
pluripotent	VB	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium,	,	O
except	IN	O
wherein	PDT	O
the	DT	O
beta-mercaptoethanol	JJ	O
concentration	NN	O
is	VBZ	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM.	.	O
A	DT	O
related	JJ	O
aspect	NN	O
of	IN	O
this	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
medium	NN	O
including	VBG	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
albumin,	,	O
minerals,	,	O
lipids,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid,	,	O
and	CC	O
lithium,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages.	.	O
It	PRP	O
is	VBZ	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
define	VB	O
culture	NN	O
conditions	NNS	O
for	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
that	WDT	O
are	VBP	O
as	RB	O
defined	VBN	O
as	IN	O
possible,	,	O
to	TO	O
allow	VB	O
the	DT	O
highest	JJS	O
percentage	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
to	TO	O
continue	VB	O
to	TO	O
proliferate	VB	O
and	CC	O
be	VB	O
maintained	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state.	.	O
Other	JJ	O
objects,	,	O
features	NNS	O
and	CC	O
advantages	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
become	VB	O
apparent	JJ	O
from	IN	O
the	DT	O
following	JJ	O
specification.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
SEVERAL	NNP	O
VIEWS	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG.	.	O
1	CD	O
illustrates	VBZ	O
optimization	NN	O
of	IN	O
physiochemical	JJ	O
conditions	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
growth;	:	O
effects	NNS	O
of	IN	O
altering	VBG	O
(a)	)	O
pH,	,	O
(b)	)	O
osmolarity,	,	O
and	CC	O
(c)	)	O
atmospheric	JJ	O
environment	NN	O
on	IN	O
cell	NN	O
proliferation,	,	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
and	CC	O
spontaneous	JJ	O
differentiation	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells.	.	O
For	IN	O
cell	NN	O
proliferation	NN	O
and	CC	O
spontaneous	JJ	O
differentiation	NN	O
experiments,	,	O
3×105	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
in	IN	O
triplicate	NN	O
wells	NNS	O
and	CC	O
analyzed	VBD	O
after	IN	O
7	CD	O
days	NNS	O
of	IN	O
growth.	.	O
For	IN	O
cloning	VBG	O
efficiency	NN	O
experiments,	,	O
5000	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
in	IN	O
triplicate	NN	O
wells	NNS	O
and	CC	O
analyzed	VBD	O
after	IN	O
14	CD	O
days	NNS	O
of	IN	O
growth.	.	O
For	IN	O
pH	NN	O
experiments,	,	O
osmolarity	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
330	CD	O
mOsMol	NN	O
and	CC	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
5%	NN	O
CO2/95%	NN	O
Air.	.	O
For	IN	O
osmolarity	NN	O
experiments,	,	O
pH	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
7.2,	,	O
and	CC	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
5%	NN	O
CO2/95%	NN	O
Air.	.	O
For	IN	O
gas	NN	O
atmosphere	NN	O
experiments,	,	O
pH	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
7.2,	,	O
and	CC	O
osmolarity	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
350±1-5	JJ	O
mOsMol.	.	O
A	DT	O
minimum	NN	O
of	IN	O
three	CD	O
independent	JJ	O
replicates	NNS	O
(in	IN	O
triplicate)	)	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
parameter.	.	O
Data	NNS	O
are	VBP	O
presented	VBN	O
+/−SEM.	.	O
*=significantly	RB	O
different	JJ	O
(P<0.05)	)	O
from	IN	O
standard	JJ	O
conditions	NNS	O
for	IN	O
each	DT	O
parameter	NN	O
(pH	JJ	O
7.0,	,	O
osmolarity	NN	O
330	CD	O
mOsMol,	,	O
atmosphere	RB	O
5%	NN	O
CO2/20%	NN	O
O2).	.	O
FIG.	.	O
2	CD	O
shows	NNS	O
growth	NN	O
curves	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
versus	NN	O
conditioned	VBD	O
medium	NN	O
(CM)	)	O
that	WDT	O
are	VBP	O
plotted	VBN	O
over	IN	O
three	CD	O
passages	NNS	O
starting	VBG	O
with	IN	O
an	DT	O
equivalent	JJ	O
number	NN	O
of	IN	O
cells	NNS	O
at	IN	O
day	NN	O
0	CD	O
for	IN	O
each	DT	O
passage	NN	O
(5×105	CD	O
cells);	:	O
for	IN	O
each	DT	O
passage,	,	O
cell	NN	O
counts	NNS	O
are	VBP	O
reported	VBN	O
(1×105	CD	O
cells)	)	O
from	IN	O
triplicate	NN	O
wells	NNS	O
at	IN	O
day	NN	O
3	CD	O
and	CC	O
day	NN	O
7;	:	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
third	JJ	O
passage,	,	O
cells	NNS	O
from	IN	O
triplicate	NN	O
wells	NNS	O
were	VBD	O
collected	VBN	O
an	DT	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell-specific	NN	O
markers.	.	O
In	IN	O
eight	CD	O
replicates	NNS	O
of	IN	O
this	DT	O
experiment	NN	O
using	VBG	O
four	CD	O
different	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines,	,	O
the	DT	O
number	NN	O
of	IN	O
cells	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
three	CD	O
passages	NNS	O
was	VBD	O
always	RB	O
greater	JJR	O
in	IN	O
TeSR1	NNP	O
than	IN	O
in	IN	O
conditioned	JJ	O
medium.	.	O
In	IN	O
the	DT	O
same	JJ	O
replicates,	,	O
the	DT	O
percentage	NN	O
of	IN	O
cells	NNS	O
expressing	VBG	O
ES	NNP	O
cell	NN	O
markers	NNS	O
in	IN	O
TeSR1	NNP	O
was	VBD	O
either	RB	O
higher	JJR	O
than	IN	O
or	CC	O
equivalent	JJ	O
to	TO	O
the	DT	O
percentage	NN	O
in	IN	O
conditioned	JJ	O
medium.	.	O
CM,	,	O
conditioned	VBD	O
medium.	.	O
FIGS.	.	O
3A-D	JJ	O
show	NN	O
a	DT	O
graphical	JJ	O
presentation	NN	O
of	IN	O
FACS	NNP	O
data	NNS	O
showing	VBG	O
the	DT	O
high	JJ	O
level	NN	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
human	JJ	O
ES	NNP	O
cell	NN	O
culture	NN	O
grown	VBN	O
in	IN	O
CM	NNP	O
(FIGS.	.	O
3	CD	O
A	DT	O
and	CC	O
C)	)	O
and	CC	O
TeSR1	NNP	O
medium	NN	O
(FIGS.	.	O
3	CD	O
B	NNP	O
and	CC	O
D),	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
expression	NN	O
of	IN	O
Oct-4	NNP	O
(FIGS.	.	O
3	CD	O
A	DT	O
and	CC	O
B)	)	O
and	CC	O
SSEA-4	NNP	O
(FIGS.	.	O
3	CD	O
C	NNP	O
and	CC	O
D).	.	O
FIG.	.	O
4	CD	O
is	VBZ	O
a	DT	O
graphical	JJ	O
representation	NN	O
of	IN	O
data	NNS	O
showing	VBG	O
that	IN	O
the	DT	O
medium	NN	O
described	VBD	O
here	RB	O
results	NNS	O
in	IN	O
robust	JJ	O
growth	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture.	.	O
Specifically,	,	O
what	WP	O
is	VBZ	O
shown	VBN	O
is	VBZ	O
growth	NN	O
curve	NN	O
analysis	NN	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1	NNP	O
(positive	JJ	O
control),	,	O
and	CC	O
TeSR1	NNP	O
minus	VBD	O
the	DT	O
following	JJ	O
individual	JJ	O
components:	:	O
TGFβ,	,	O
pipecolic	JJ	O
acid	NN	O
(PA),	,	O
GABA,	,	O
LiCl	NNP	O
and	CC	O
bFGF,	,	O
and	CC	O
TeSR1	NNP	O
minus	VBP	O
all	DT	O
five	CD	O
growth	NN	O
factors	NNS	O
(TeSR1−ALL	NNP	O
or	CC	O
negative	JJ	O
control);	:	O
3×105	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
at	IN	O
day	NN	O
0	CD	O
of	IN	O
each	DT	O
passage.	.	O
FIG.	.	O
5	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
from	IN	O
experimental	JJ	O
work	NN	O
described	VBD	O
here	RB	O
below.	.	O
This	DT	O
shows	VBZ	O
that	IN	O
the	DT	O
omission	NN	O
of	IN	O
each	DT	O
component	NN	O
from	IN	O
the	DT	O
medium	NN	O
results	NNS	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
differentiated	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
culture	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells,	,	O
and	CC	O
thus	RB	O
it	PRP	O
can	MD	O
be	VB	O
inferred	VBN	O
that	IN	O
the	DT	O
inverse	NN	O
is	VBZ	O
true	JJ	O
(i.e.,	,	O
the	DT	O
addition	NN	O
of	IN	O
each	DT	O
component	NN	O
in	IN	O
the	DT	O
medium	NN	O
reduces	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
differentiated	JJ	O
cells).	.	O
This	DT	O
is	VBZ	O
shown	VBN	O
through	IN	O
the	DT	O
percent	NN	O
expression	NN	O
of	IN	O
the	DT	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81,	,	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components:	:	O
TGFβ,	,	O
PA,	,	O
GABA,	,	O
LiCl	NNP	O
and	CC	O
bFGF;	:	O
data	NNS	O
are	VBP	O
reported	VBN	O
+/−standard	JJ	O
deviation;	:	O
“*”	CC	O
indicates	VBZ	O
significant	JJ	O
difference	NN	O
(t-test	JJ	O
P<0.05)	)	O
from	IN	O
TeSR1.	.	O
FIG.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
for	IN	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4,	,	O
SSEA-4,	,	O
SSEA-1,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components:	:	O
TGFβ,	,	O
pipecolic	JJ	O
acid	NN	O
(PA),	,	O
GABA,	,	O
LiCl	NNP	O
and	CC	O
bFGF.	.	O
Triplicate	NNP	O
wells	NNS	O
of	IN	O
resulting	VBG	O
cells	NNS	O
were	VBD	O
analyzed	VBN	O
on	IN	O
day	NN	O
6	CD	O
of	IN	O
passage	NN	O
3	CD	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
markers.	.	O
All	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
for	IN	O
the	DT	O
H1	NNP	O
cell	NN	O
line;	:	O
similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
cell	NN	O
lines	NNS	O
H7,	,	O
H9	NNP	O
and	CC	O
H14.	.	O
Data	NNS	O
are	VBP	O
reported	VBN	O
±standard	JJ	O
deviation.	.	O
*,	,	O
significantly	RB	O
different	JJ	O
(t-test,	,	O
P<0.05)	)	O
from	IN	O
TeSR1.	.	O
FIG.	.	O
7	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
for	IN	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4,	,	O
and	CC	O
cell	NN	O
proliferation	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components:	:	O
TGFβ,	,	O
LiCl,	,	O
bFGF,	,	O
pipecolic	JJ	O
acid	NN	O
(PA)	)	O
and	CC	O
GABA.	.	O
FIGS.	.	O
8A-B	JJ	O
shows	VBZ	O
the	DT	O
karyotype	JJ	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium;	:	O
H9	NNP	O
(a)	)	O
and	CC	O
H14	NNP	O
(b)	)	O
cell	NN	O
lines	NNS	O
were	VBD	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
matrix	NN	O
for	IN	O
21	CD	O
and	CC	O
7	CD	O
passages	NNS	O
(FIG.	.	O
8A),	,	O
respectively,	,	O
and	CC	O
subjected	VBN	O
to	TO	O
cytogenetic	JJ	O
analysis	NN	O
using	VBG	O
G-banding	NNP	O
(FIG.	.	O
8B);	:	O
20	CD	O
metaphase	NN	O
cells	NNS	O
from	IN	O
each	DT	O
cell	NN	O
line	NN	O
were	VBD	O
evaluated.	.	O
A	DT	O
normal	JJ	O
karyotype	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
all	DT	O
cells	NNS	O
examined.	.	O
FIG.	.	O
9	CD	O
illustrates	NNS	O
pluripotency	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
maintained	VBD	O
in	IN	O
TeSR1	NNP	O
medium;	:	O
H1	NNP	O
and	CC	O
H9	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
for	IN	O
11	CD	O
and	CC	O
20	CD	O
passages,	,	O
respectively,	,	O
and	CC	O
injected	VBD	O
into	IN	O
the	DT	O
rear	JJ	O
leg	JJ	O
muscle	NN	O
of	IN	O
4-week-old	JJ	O
SCID-beige	JJ	O
mice.	.	O
Teratomas	NNP	O
exhibiting	VBG	O
complex	JJ	O
differentiation	NN	O
developed	VBN	O
in	IN	O
the	DT	O
mice	JJ	O
6-8	JJ	O
weeks	NNS	O
post-inoculation:	:	O
(a)	)	O
bone,	,	O
H9	NNP	O
cell	NN	O
line,	,	O
(b)	)	O
epithelial	JJ	O
acinar	NN	O
structure,	,	O
H1	NNP	O
cell	NN	O
line,	,	O
(c)	)	O
epithelial	JJ	O
luminal	JJ	O
structure,	,	O
H9	NNP	O
cell	NN	O
line,	,	O
(d)	)	O
epithelial	JJ	O
luminal	JJ	O
structure,	,	O
H1	NNP	O
cell	NN	O
line,	,	O
(e)	)	O
cartilage,	,	O
H9	NNP	O
cell	NN	O
line,	,	O
(f)	)	O
cartilage	NN	O
with	IN	O
epithelial	JJ	O
structure,	,	O
H1	NNP	O
cell	NN	O
line,	,	O
(g)	)	O
rosettes	VBZ	O
of	IN	O
neural	JJ	O
epithelium,	,	O
H9	NNP	O
cell	NN	O
line,	,	O
(h)	)	O
and	CC	O
loosely	RB	O
structured	JJ	O
mesenchyme,	,	O
H1	NNP	O
cell	NN	O
line;	:	O
scale	JJ	O
bar=100	NN	O
um.	.	O
FIG.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
matrix	NN	O
composition	NN	O
on	IN	O
cell	NN	O
proliferation	NN	O
and	CC	O
differentiation,	,	O
as	IN	O
measured	VBN	O
by	IN	O
Oct-4	NNP	O
expression	NN	O
and	CC	O
cell	NN	O
proliferation.	.	O
CVFL	NNP	O
refers	NNS	O
to	TO	O
the	DT	O
Matrigel™	NNP	O
substitute,	,	O
which	WDT	O
contains	VBZ	O
human	JJ	O
products	NNS	O
or	CC	O
recombinant	JJ	O
proteins,	,	O
including	VBG	O
collagen	NN	O
(C),	,	O
vitronectin	FW	O
(V),	,	O
fibronectin	NN	O
(F)	)	O
and	CC	O
laminin	$	O
(L)	)	O
that	WDT	O
support	NN	O
cell	NN	O
growth	NN	O
and	CC	O
prevent	NN	O
differentiation.	.	O
These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
all	DT	O
four	CD	O
matrix	NN	O
components	NNS	O
are	VBP	O
not	RB	O
necessary	JJ	O
to	TO	O
support	VB	O
cell	NN	O
growth	NN	O
and	CC	O
prevent	NN	O
differentiation.	.	O
FIG.	.	O
11	CD	O
shows	NNS	O
representative	JJ	O
morphology	NN	O
and	CC	O
FACS	NNP	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
defined,	,	O
feeder-independent	JJ	O
conditions.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
5	CD	O
passages	NNS	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
and	CC	O
then	RB	O
photographed	VBD	O
at	IN	O
magnifications	NNS	O
of	IN	O
2×	CD	O
(a),	,	O
4×	CD	O
(b),	,	O
and	CC	O
10×	CD	O
(c)	)	O
using	VBG	O
phase	NN	O
contrast	NN	O
microscopy.	.	O
Cells	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
internal	JJ	O
(Oct-4)	)	O
or	CC	O
cell	NN	O
surface	NN	O
(SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
Tra	NNP	O
1-81)	)	O
markers	NNS	O
after	IN	O
11	CD	O
passages	NNS	O
of	IN	O
culture	NN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
(d-g).	.	O
The	DT	O
level	NN	O
of	IN	O
undifferentiation	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
90%	NN	O
or	CC	O
greater	JJR	O
based	VBN	O
on	IN	O
percent	NN	O
positive	JJ	O
cell	NN	O
marker	NN	O
expression	NN	O
listed	VBN	O
in	IN	O
parentheses	NNS	O
and	CC	O
data	NNS	O
presented	VBN	O
are	VBP	O
from	IN	O
the	DT	O
H1	NNP	O
cell	NN	O
line.	.	O
Similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
the	DT	O
H9	NNP	O
cell	NN	O
line	NN	O
with	IN	O
16	CD	O
passages	NNS	O
of	IN	O
culture	NN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components.	.	O
FIG.	.	O
12	CD	O
illustrates	VBZ	O
the	DT	O
absence	NN	O
of	IN	O
sialic	JJ	O
acid	JJ	O
contamination	NN	O
in	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
defined	JJ	O
conditions.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
grown	VBN	O
under	IN	O
different	JJ	O
conditions	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
LC-MS	NNP	O
for	IN	O
the	DT	O
sialic	JJ	O
acids	NNS	O
Neu5Ac	NNP	O
and	CC	O
Neu5Gc:	:	O
(a)	)	O
the	DT	O
common	JJ	O
form,	,	O
NeuAc	NNP	O
was	VBD	O
found	VBN	O
abundantly	RB	O
expressed	VBN	O
on	IN	O
cells	NNS	O
regardless	RB	O
of	IN	O
culture	NN	O
conditions	NNS	O
with	IN	O
peak	JJ	O
intensities	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
1-3×108	JJ	O
(traces	NNS	O
autoscaled);	:	O
and	CC	O
(b)	)	O
the	DT	O
non-human	JJ	O
Neu5Gc	NNP	O
was	VBD	O
found	VBN	O
on	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
grown	VBN	O
under	IN	O
standard	NN	O
(conditioned	JJ	O
medium)	)	O
conditions	NNS	O
(peak	JJ	O
intensity	NN	O
off	IN	O
scale	NN	O
at	IN	O
5×105),	,	O
it	PRP	O
was	VBD	O
reduced	VBN	O
but	CC	O
detectable	JJ	O
in	IN	O
partially	RB	O
humanized	VBN	O
conditions	NNS	O
with	IN	O
peak	JJ	O
intensity	NN	O
of	IN	O
4×104,	,	O
and	CC	O
no	DT	O
detectable	JJ	O
Neu5Gc	NNP	O
was	VBD	O
found	VBN	O
on	IN	O
cells	NNS	O
grown	VBN	O
in	IN	O
fully	RB	O
humanized	VBN	O
conditions.	.	O
Growth	NNP	O
conditions	NNS	O
key:	:	O
Standard	NNP	O
Conditions=mouse	NNP	O
embryonic	JJ	O
fibroblast	NN	O
conditioned	VBD	O
media	NNS	O
on	IN	O
Matrigel	NNP	O
(orange).	.	O
Partially	RB	O
Humanized=TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
(green),	,	O
Fully	NNP	O
Humanized=TeSR1	NNP	O
medium	NN	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
(blue).	.	O
FIG.	.	O
13	CD	O
shows	NNS	O
representative	JJ	O
morphology,	,	O
RT-PCR	NNP	O
and	CC	O
FACS	NNP	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
derived	VBN	O
and	CC	O
maintained	VBN	O
in	IN	O
defined,	,	O
feeder-independent	JJ	O
culture	NN	O
conditions:	:	O
(a)	)	O
WA	$	O
16	CD	O
cells	NNS	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
for	IN	O
16	CD	O
passages	NNS	O
were	VBD	O
photographed	VBN	O
at	IN	O
4×	CD	O
magnification	NN	O
using	VBG	O
phase	NN	O
contrast	NN	O
microscopy	NN	O
(scale	JJ	O
bar,	,	O
100	CD	O
μm);	:	O
(b)	)	O
RT-PCR	NNP	O
analysis	NN	O
of	IN	O
total	JJ	O
RNA	NNP	O
isolated	VBD	O
from	IN	O
control	NN	O
cells	NNS	O
(H1)	)	O
or	CC	O
newly	RB	O
derived	VBN	O
cell	NN	O
lines	NNS	O
(WA15	NNP	O
and	CC	O
WA16),	,	O
primer	JJ	O
sets	NNS	O
for	IN	O
pluripotency	NN	O
markers	NNS	O
(Oct-4,	,	O
Nanog,	,	O
Rex1,	,	O
hTERT)	)	O
and	CC	O
a	DT	O
housekeeping	NN	O
gene	NN	O
(β-actin)	)	O
were	VBD	O
analyzed	VBN	O
with	IN	O
(+)	)	O
or	CC	O
without	IN	O
(−)	)	O
RNA;	:	O
and	CC	O
(c)	)	O
WA15	NNP	O
cells	NNS	O
were	VBD	O
FACS	NNP	O
analyzed	VBD	O
after	IN	O
18	CD	O
passages	NNS	O
for	IN	O
internal	JJ	O
(Oct-4)	)	O
or	CC	O
cell	NN	O
surface	NN	O
(SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
Tra	NNP	O
1-81)	)	O
markers.	.	O
Percentage	NN	O
of	IN	O
positive	JJ	O
cells	NNS	O
is	VBZ	O
listed	VBN	O
in	IN	O
parentheses.	.	O
FIGS.	.	O
14A-B	JJ	O
illustrates	VBZ	O
the	DT	O
karyotype	NN	O
of	IN	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
derived	VBN	O
and	CC	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
for	IN	O
5	CD	O
months	NNS	O
(FIG.	.	O
14A)	)	O
were	VBD	O
subjected	VBN	O
to	TO	O
cytogenetic	JJ	O
analysis	NN	O
using	VBG	O
G-banding	NNP	O
(FIG.	.	O
14B);	:	O
twenty	JJ	O
metaphase	NN	O
cells	NNS	O
from	IN	O
each	DT	O
of	IN	O
the	DT	O
cell	NN	O
lines	NNS	O
were	VBD	O
evaluated:	:	O
(a)	)	O
a	DT	O
normal	JJ	O
46XY	CD	O
karyotype	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
all	DT	O
WA15	NNP	O
cells,	,	O
while	IN	O
(b)	)	O
all	DT	O
20	CD	O
WA16	NNP	O
cells	NNS	O
demonstrated	VBD	O
a	DT	O
47XXY	CD	O
karyotype.	.	O
FIG.	.	O
15	CD	O
illustrates	VBZ	O
the	DT	O
growth	NN	O
of	IN	O
hES	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
mTeSR1	NN	O
with	IN	O
five	CD	O
different	JJ	O
concentrations	NNS	O
of	IN	O
beta	NN	O
mercaptoethanol	NN	O
(βME).	.	O
ES03-DL1-K	NNP	O
were	VBD	O
grown	VBN	O
for	IN	O
one	CD	O
to	TO	O
five	CD	O
passages,	,	O
visualized	VBN	O
(a),	,	O
counted	VBN	O
to	TO	O
determine	VB	O
proliferation	NN	O
and	CC	O
cloning	VBG	O
efficiency	NN	O
(b),	,	O
and	CC	O
stained	VBD	O
using	VBG	O
Trypan	NNP	O
Blue	NNP	O
for	IN	O
Oct-4	NNP	O
and	CC	O
SSEA-4	NNP	O
to	TO	O
identify	VB	O
differentiation	NN	O
status	NN	O
of	IN	O
the	DT	O
cells	NNS	O
(c).	.	O
The	DT	O
treatment	NN	O
concentrations	NNS	O
consisted	VBD	O
of	IN	O
0,	,	O
1.75,	,	O
3.5,	,	O
7,	,	O
and	CC	O
14	CD	O
μL	NN	O
βME/500	NNP	O
mL	NN	O
of	IN	O
total	JJ	O
TeSR1	NNP	O
media.	.	O
Results	NNS	O
shown	VBN	O
are	VBP	O
the	DT	O
mean	NN	O
from	IN	O
growth	NN	O
in	IN	O
3	CD	O
wells/treatment.	.	O
This	DT	O
experiment	NN	O
was	VBD	O
repeated	VBN	O
multiple	JJ	O
times	NNS	O
both	DT	O
with	IN	O
ES03-DL1-K	NNP	O
and	CC	O
H9-WA09	NNP	O
cells	NNS	O
with	IN	O
similar	JJ	O
results.	.	O
FIG.	.	O
16	CD	O
illustrates	VBZ	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
culture	NN	O
and	CC	O
maintain	NN	O
iPS	NN	O
cells.	.	O
Here	RB	O
pluripotent	JJ	O
cells	NNS	O
were	VBD	O
generated	VBN	O
from	IN	O
two	CD	O
iPS	NN	O
cell	NN	O
lines,	,	O
each	DT	O
having	VBG	O
gone	VBN	O
through	IN	O
at	IN	O
least	JJS	O
10	CD	O
passages	NNS	O
in	IN	O
modified	JJ	O
TeSR1	NNP	O
medium.	.	O
(A)	)	O
Flow	NNP	O
cytometry	NN	O
data	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
iPS	NN	O
cell	NN	O
line	NN	O
IMR90,	,	O
cultured	VBD	O
for	IN	O
at	IN	O
least	JJS	O
10	CD	O
passages	NNS	O
in	IN	O
mTeSR1,	,	O
maintained	VBD	O
greater	JJR	O
than	IN	O
95%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells.	.	O
(B)	)	O
flow	VBP	O
cytometry	NN	O
data	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
vector-free	JJ	O
iPS	NN	O
cell	NN	O
line	NN	O
iPS-DF-19-9,	,	O
cultured	VBN	O
for	IN	O
at	IN	O
least	JJS	O
16	CD	O
passages	NNS	O
in	IN	O
mTeSR1,	,	O
maintained	VBD	O
more	JJR	O
than	IN	O
98%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Currently,	,	O
large	JJ	O
scale	NN	O
culturing	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
(embryonic	JJ	O
and	CC	O
induced	JJ	O
pluripotent	NN	O
stem	NN	O
cells)	)	O
for	IN	O
use	NN	O
in	IN	O
regenerative	JJ	O
medicine	NN	O
and	CC	O
drug	NN	O
discovery	NN	O
applications	NNS	O
is	VBZ	O
a	DT	O
major	JJ	O
challenge	NN	O
in	IN	O
biomedical	JJ	O
research	NN	O
and	CC	O
the	DT	O
pharmaceutical	JJ	O
industry.	.	O
To	TO	O
overcome	VB	O
this	DT	O
bottleneck,	,	O
stem	NN	O
cell	JJ	O
culture	NN	O
conditions,	,	O
including	VBG	O
medium	NN	O
composition,	,	O
and	CC	O
culturing	VBG	O
processes	NNS	O
must	MD	O
become	VB	O
robust,	,	O
reproducible,	,	O
and	CC	O
capable	JJ	O
of	IN	O
generating	VBG	O
sufficient	JJ	O
numbers	NNS	O
of	IN	O
cells	NNS	O
while	IN	O
still	RB	O
maintaining	VBG	O
a	DT	O
stable	JJ	O
stem	NN	O
cell	NN	O
phenotype.	.	O
To	TO	O
meet	VB	O
this	DT	O
challenge,	,	O
the	DT	O
inventors	NNS	O
describe	VBP	O
here	RB	O
multiple	JJ	O
culture	NN	O
conditions	NNS	O
and	CC	O
media,	,	O
which	WDT	O
permit	VBP	O
the	DT	O
indefinite	JJ	O
culture	NN	O
and	CC	O
robust	JJ	O
proliferation	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
with	IN	O
continued	JJ	O
expression	NN	O
of	IN	O
characteristic	JJ	O
pluripotency	NN	O
markers.	.	O
Also,	,	O
the	DT	O
media	NNS	O
described	VBN	O
are	VBP	O
prepared	VBN	O
in	IN	O
the	DT	O
complete	JJ	O
absence	NN	O
of	IN	O
both	DT	O
feeder	NN	O
cells	NNS	O
and	CC	O
conditioned	JJ	O
medium.	.	O
As	IN	O
described	VBN	O
here,	,	O
the	DT	O
defined	JJ	O
culture	NN	O
conditions	NNS	O
and	CC	O
media	NNS	O
are	VBP	O
suitable	JJ	O
for	IN	O
use	NN	O
with	IN	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cells.	.	O
Pluripotent	NNP	O
cells	NNS	O
express	VBP	O
one	CD	O
or	CC	O
more	JJR	O
pluripotent	JJ	O
cell-specific	JJ	O
marker,	,	O
such	JJ	O
as	IN	O
Oct-4,	,	O
SSEA-3,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60,	,	O
Tra	NNP	O
1-81.	.	O
They	PRP	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
human	JJ	O
ES	NNP	O
cells	NNS	O
(e.g.,	,	O
H1,	,	O
H7,	,	O
H9	NNP	O
and	CC	O
H14),	,	O
iPS	JJ	O
cells	NNS	O
(e.g.,	,	O
iPS-Foreskin	JJ	O
and	CC	O
iPS-IMR90),	,	O
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells	NNS	O
(e.g.,	,	O
iPS-DF19-9,	,	O
iPS-DF4-3,	,	O
and	CC	O
iPS-DF6-9),	,	O
which	WDT	O
are	VBP	O
all	DT	O
available	JJ	O
through	IN	O
WiCell®	NNP	O
International	NNP	O
Stem	NNP	O
Cell	NNP	O
(WISC)	)	O
Bank	NNP	O
(Madison,	,	O
Wis.).	.	O
iPS	NN	O
cells	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Yu	NNP	B
J.	NNP	I
et	FW	I
al.	.	I
Science,	,	I
318(5858),	,	I
pp.	.	I
1917-1920	CD	I
(2007)	)	I
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Yu	NNP	B
J.	NNP	I
et	FW	I
al.	.	I
Science,	,	I
324(5928),	,	I
pp.	.	I
797-801	CD	I
(2009),	,	I
both	DT	O
of	IN	O
these	DT	O
references	NNS	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
their	PRP$	O
entirety.	.	O
For	IN	O
some	DT	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
including	VBG	O
iPS	NN	O
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells,	,	O
certificate	NN	O
of	IN	O
analyses	NNS	O
for	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
on	IN	O
growth	NN	O
matrix	NN	O
using	VBG	O
the	DT	O
fully	RB	O
defined	VBN	O
medium	NN	O
disclosed	VBN	O
here	RB	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
WISC	NNP	O
website.	.	O
Additional	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
disease	VB	O
model	NN	O
cell	NN	O
lines	NNS	O
and	CC	O
genetically	RB	O
modified	VBN	O
lines	NNS	O
containing	VBG	O
marker	NN	O
genes.	.	O
In	IN	O
many	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention,	,	O
the	DT	O
culture	NN	O
conditions	NNS	O
and	CC	O
media	NNS	O
are	VBP	O
entirely	RB	O
free	JJ	O
of	IN	O
non-human	JJ	O
animal	NN	O
products	NNS	O
and	CC	O
all	DT	O
proteins	NNS	O
used	VBN	O
are	VBP	O
of	IN	O
human	JJ	O
origin.	.	O
The	DT	O
development	NN	O
of	IN	O
these	DT	O
media	NNS	O
and	CC	O
culture	NN	O
conditions	NNS	O
make	VBP	O
possible	JJ	O
the	DT	O
derivation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
in	IN	O
defined	JJ	O
and	CC	O
controlled	JJ	O
conditions	NNS	O
without	IN	O
direct	JJ	O
or	CC	O
indirect	JJ	O
exposure	NN	O
to	TO	O
non-human	JJ	O
animal	JJ	O
cells	NNS	O
of	IN	O
any	DT	O
kind.	.	O
Also,	,	O
the	DT	O
media	NNS	O
and	CC	O
culture	NN	O
conditions	NNS	O
described	VBD	O
here	RB	O
enable	JJ	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
which	WDT	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
non-human	JJ	O
cells	NNS	O
or	CC	O
a	DT	O
to	TO	O
medium	NN	O
in	IN	O
which	WDT	O
animal	JJ	O
cells	NNS	O
were	VBD	O
cultured.	.	O
Specifically,	,	O
the	DT	O
media	NNS	O
disclosed	VBD	O
here	RB	O
permit	VBZ	O
the	DT	O
culture	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
primate	NN	O
and	CC	O
preferably	RB	O
human	JJ	O
ES	NNP	O
and	CC	O
iPS	JJ	O
cells.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
the	DT	O
medium	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
animal	JJ	O
products	NNS	O
or	CC	O
proteins.	.	O
This	DT	O
medium	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
to	TO	O
support	VB	O
undifferentiated	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
proliferation	NN	O
through	IN	O
at	IN	O
least	JJS	O
twenty-five	JJ	O
passages,	,	O
which	WDT	O
is	VBZ	O
firm	JJ	O
evidence	NN	O
that	IN	O
it	PRP	O
will	MD	O
support	VB	O
such	JJ	O
cultures	NNS	O
indefinitely.	.	O
A	DT	O
suitable	JJ	O
medium	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
supporting	VBG	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
human	JJ	O
ES	NNP	O
and	CC	O
iPS	NN	O
cell	NN	O
lines,	,	O
and	CC	O
derived	VBD	O
using	VBG	O
the	DT	O
media	NNS	O
described	VBD	O
herein	RB	O
after	IN	O
as	IN	O
“new	JJ	O
lines”.	.	O
These	DT	O
lines	NNS	O
have	VBP	O
passed	VBN	O
through	IN	O
more	JJR	O
than	IN	O
ten	JJ	O
passages	NNS	O
in	IN	O
culture.	.	O
In	IN	O
the	DT	O
past,	,	O
use	NN	O
of	IN	O
conditioned	JJ	O
medium	NN	O
has	VBZ	O
sometimes	RB	O
been	VBN	O
referred	VBN	O
to	TO	O
as	IN	O
creating	VBG	O
“feeder-free”	JJ	O
culture	NN	O
conditions.	.	O
This	DT	O
phrase	NN	O
is	VBZ	O
a	DT	O
misnomer,	,	O
since	IN	O
feeder	NN	O
cells	NNS	O
of	IN	O
some	DT	O
type	NN	O
are	VBP	O
still	RB	O
needed	VBN	O
to	TO	O
condition	VB	O
the	DT	O
“conditioned	JJ	O
medium.”	NN	O
As	IN	O
described	NN	O
here,	,	O
culture	NN	O
conditions	NNS	O
permit	VBP	O
the	DT	O
“feeder-independent”	JJ	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells.	.	O
By	IN	O
“feeder-independent”	JJ	O
it	PRP	O
is	VBZ	O
meant	VBN	O
that	IN	O
no	DT	O
feeder	NN	O
cells	NNS	O
of	IN	O
any	DT	O
kind,	,	O
human	NN	O
or	CC	O
animal,	,	O
are	VBP	O
needed	VBN	O
anywhere	RB	O
in	IN	O
the	DT	O
process	NN	O
and	CC	O
are	VBP	O
neither	RB	O
required	VBN	O
for	IN	O
culture	NN	O
nor	CC	O
to	TO	O
condition	VB	O
the	DT	O
medium.	.	O
Feeder-independent	JJ	O
conditions	NNS	O
do	VBP	O
not	RB	O
require	VB	O
feeder	NN	O
cells	NNS	O
at	IN	O
all	DT	O
for	IN	O
any	DT	O
purpose.	.	O
A	DT	O
defined	JJ	O
and	CC	O
humanized	JJ	O
medium	NN	O
for	IN	O
the	DT	O
culture	NN	O
and	CC	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
typically	RB	O
includes	VBZ	O
salts,	,	O
vitamins,	,	O
lipids,	,	O
an	DT	O
energy	NN	O
source	NN	O
such	JJ	O
as	IN	O
glucose,	,	O
minerals,	,	O
amino	JJ	O
acids,	,	O
growth	NN	O
factors	NNS	O
and	CC	O
other	JJ	O
components.	.	O
As	IN	O
a	DT	O
supplement	NN	O
to	TO	O
support	VB	O
cell	NN	O
growth,	,	O
stem	NN	O
cell	NN	O
media	NNS	O
have	VBP	O
included	VBN	O
serum	NN	O
from	IN	O
one	CD	O
source	NN	O
or	CC	O
another.	.	O
Also,	,	O
previously	RB	O
it	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
FGF	NNP	O
plus	CC	O
a	DT	O
serum	JJ	O
replacement	NN	O
additive	JJ	O
permits	VBZ	O
the	DT	O
cultivation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
serum.	.	O
The	DT	O
serum	JJ	O
replacement	NN	O
additive	NN	O
can	MD	O
be	VB	O
a	DT	O
commercially	RB	O
available	JJ	O
product	NN	O
sold	VBN	O
for	IN	O
that	DT	O
purpose	NN	O
or	CC	O
can	MD	O
be	VB	O
a	DT	O
formulated	JJ	O
mixture	NN	O
of	IN	O
proteins,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
serum	VB	O
albumin,	,	O
vitamins,	,	O
minerals,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute,	,	O
and	CC	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute.	.	O
The	DT	O
albumin,	,	O
insulin	NN	O
and	CC	O
transferrin	NN	O
may	MD	O
be	VB	O
recombinant	JJ	O
proteins.	.	O
This	DT	O
serum	JJ	O
replacement	NN	O
additive	NN	O
may	MD	O
also	RB	O
be	VB	O
supplemented	VBN	O
with,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to,	,	O
selenium	NN	O
and	CC	O
a	DT	O
mixture	NN	O
of	IN	O
lipids.	.	O
Preferably,	,	O
a	DT	O
defined	JJ	O
serum	NN	O
replacement	NN	O
mix	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
lieu	NN	O
of	IN	O
serum	NN	O
from	IN	O
any	DT	O
source	NN	O
in	IN	O
culturing	VBG	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
to	TO	O
avoid	VB	O
variation	NN	O
in	IN	O
serum	NN	O
constituents	NNS	O
and	CC	O
to	TO	O
use	VB	O
media	NNS	O
that	WDT	O
are	VBP	O
as	RB	O
defined	VBN	O
as	IN	O
possible.	.	O
Other	JJ	O
growth	NN	O
factors	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
advantageous	JJ	O
additives	NNS	O
to	TO	O
the	DT	O
culture	NN	O
medium	NN	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
gamma-aminobutyric	JJ	O
acid	NN	O
(GABA),	,	O
pipecolic	JJ	O
acid	NN	O
(PA),	,	O
lithium	JJ	O
chloride	NN	O
(LiCl)	)	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
(TGFβ).	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
found	VBN	O
that	IN	O
TGFβ	NNP	O
may	MD	O
not	RB	O
be	VB	O
needed	VBN	O
when	WRB	O
increasing	VBG	O
levels	NNS	O
of	IN	O
FGF	NNP	O
are	VBP	O
added	VBN	O
to	TO	O
the	DT	O
medium.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
other	JJ	O
lithium	NN	O
salts	NNS	O
can	MD	O
substitute	VB	O
for	IN	O
LiCl	NNP	O
in	IN	O
the	DT	O
cell	NN	O
culture	NN	O
medium.	.	O
These	DT	O
may	MD	O
include	VB	O
lithium	NN	O
salts,	,	O
wherein	VBP	O
the	DT	O
anion	NN	O
includes,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to,	,	O
chloride,	,	O
bromide,	,	O
carbonate,	,	O
citrate,	,	O
sulfate,	,	O
or	CC	O
other	JJ	O
biologically	RB	O
compatible	JJ	O
monovalent	NN	O
anion	NN	O
(see,	,	O
for	IN	O
example,	,	O
US	NNP	O
2004/0028656	CD	O
and	CC	O
WO	NNP	O
2008/055224).	.	O
To	TO	O
avoid	VB	O
the	DT	O
need	NN	O
for	IN	O
a	DT	O
fibroblast	JJ	O
feeder	NN	O
layer,	,	O
previously	RB	O
thought	VBN	O
to	TO	O
be	VB	O
necessary	JJ	O
to	TO	O
maintain	VB	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
(ES	NNP	O
and	CC	O
iPS	VB	O
cells)	)	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state,	,	O
it	PRP	O
is	VBZ	O
reported	VBN	O
here	RB	O
that	IN	O
combining	VBG	O
the	DT	O
use	NN	O
of	IN	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
FGF	NNP	O
(10	CD	O
to	TO	O
1000	CD	O
ng/ml)	)	O
together	RB	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
GABA,	,	O
PA,	,	O
Li	NNP	O
and	CC	O
TGFβ,	,	O
will	MD	O
enable	VB	O
a	DT	O
medium	NN	O
to	TO	O
support	VB	O
long	JJ	O
term	NN	O
(at	IN	O
least	JJS	O
three	CD	O
passages,	,	O
and	CC	O
suitably	RB	O
170	CD	O
passages)	)	O
undifferentiated	JJ	O
stem	NN	O
cell	NN	O
growth.	.	O
The	DT	O
combination	NN	O
of	IN	O
these	DT	O
additives	NNS	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
sufficient	JJ	O
to	TO	O
maintain	VB	O
the	DT	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
indefinitely	RB	O
without	IN	O
exposure	NN	O
to	TO	O
either	DT	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media.	.	O
These	DT	O
additives	NNS	O
are	VBP	O
demonstrably	RB	O
sufficient.	.	O
However,	,	O
all	DT	O
of	IN	O
them	PRP	O
may	MD	O
not	RB	O
be	VB	O
necessary	JJ	O
for	IN	O
every	DT	O
medium	NN	O
formulation.	.	O
By	IN	O
selective	JJ	O
deletion	NN	O
of	IN	O
these	DT	O
additives,	,	O
it	PRP	O
may	MD	O
be	VB	O
empirically	RB	O
determined	VBN	O
if	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
them	PRP	O
is	VBZ	O
not	RB	O
required	VBN	O
to	TO	O
achieve	VB	O
this	DT	O
result	NN	O
for	IN	O
a	DT	O
given	VBN	O
medium.	.	O
However,	,	O
it	PRP	O
is	VBZ	O
clear	JJ	O
that	IN	O
the	DT	O
combination	NN	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
enable	VB	O
a	DT	O
variety	NN	O
of	IN	O
media	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
long-term	JJ	O
culture	NN	O
and	CC	O
proliferation	NN	O
of	IN	O
undifferentiated	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium.	.	O
These	DT	O
additives	NNS	O
are	VBP	O
subject	JJ	O
to	TO	O
some	DT	O
variation.	.	O
For	IN	O
example,	,	O
GABA	NNP	O
is	VBZ	O
believed	VBN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
GABA	NNP	O
receptor	NN	O
and	CC	O
the	DT	O
scientific	JJ	O
literature	NN	O
includes	VBZ	O
the	DT	O
identification	NN	O
of	IN	O
several	JJ	O
molecules	NNS	O
which	WDT	O
are	VBP	O
agonists	NNS	O
of	IN	O
that	DT	O
same	JJ	O
receptor	NN	O
and	CC	O
might	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
GABA	NNP	O
in	IN	O
the	DT	O
medium	NN	O
as	IN	O
an	DT	O
equivalent.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
believed	VBN	O
that	IN	O
PA	NNP	O
also	RB	O
interacts	VBZ	O
with	IN	O
the	DT	O
GABA	NNP	O
receptor.	.	O
While	IN	O
both	DT	O
PA	NNP	O
and	CC	O
GABA	NNP	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
helpful	JJ	O
in	IN	O
the	DT	O
medium	NN	O
at	IN	O
the	DT	O
concentrations	NNS	O
used	VBN	O
here,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
envisioned	VBN	O
that	IN	O
one	CD	O
or	CC	O
the	DT	O
other	JJ	O
of	IN	O
these	DT	O
constituents	NNS	O
could	MD	O
be	VB	O
increased	VBN	O
in	IN	O
concentration	NN	O
to	TO	O
obviate	VB	O
the	DT	O
need	NN	O
for	IN	O
the	DT	O
other.	.	O
The	DT	O
FGF	NNP	O
in	IN	O
higher	JJR	O
concentrations	NNS	O
(40	CD	O
to	TO	O
100	CD	O
ng/ml)	)	O
seems	VBZ	O
to	TO	O
obviate	VB	O
the	DT	O
need	NN	O
for	IN	O
feeder	NN	O
cells.	.	O
The	DT	O
preferred	JJ	O
FGF	NNP	O
is	VBZ	O
bFGF,	,	O
also	RB	O
referred	VBD	O
to	TO	O
as	IN	O
FGF2,	,	O
but	CC	O
other	JJ	O
FGFs,	,	O
including	VBG	O
at	IN	O
least	JJS	O
FGF4,	,	O
FGF9,	,	O
FGF17,	,	O
and	CC	O
FGF18,	,	O
will	MD	O
suffice	VB	O
for	IN	O
this	DT	O
purpose	NN	O
as	RB	O
well.	.	O
Other	JJ	O
FGFs	NNP	O
may	MD	O
also	RB	O
work,	,	O
even	RB	O
if	IN	O
at	IN	O
higher	JJR	O
concentrations,	,	O
which	WDT	O
can	MD	O
be	VB	O
empirically	RB	O
determined	VBN	O
by	IN	O
researchers.	.	O
Initial	JJ	O
subjective	JJ	O
screens	NNS	O
performed	VBN	O
by	IN	O
the	DT	O
inventors	NNS	O
identified	VBD	O
several	JJ	O
growth	NN	O
factors,	,	O
chosen	NNS	O
based	VBN	O
on	IN	O
the	DT	O
receptors	NNS	O
expressed	VBN	O
by	IN	O
the	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells,	,	O
as	IN	O
having	VBG	O
positive	JJ	O
effects	NNS	O
on	IN	O
undifferentiated	JJ	O
proliferation.	.	O
Of	IN	O
these,	,	O
bFGF,	,	O
LiCl,	,	O
GABA,	,	O
PA,	,	O
and	CC	O
TGFβ	NNP	O
were	VBD	O
ultimately	RB	O
included	VBN	O
in	IN	O
TeSR1.	.	O
For	IN	O
each	DT	O
of	IN	O
the	DT	O
multiple	NN	O
cell	NN	O
lines	NNS	O
tested,	,	O
the	DT	O
proliferation	NN	O
rate	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
cells	NNS	O
maintaining	VBG	O
expression	NN	O
of	IN	O
characteristic	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
markers	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
TeSR1	NNP	O
than	IN	O
in	IN	O
control	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
fibroblast-conditioned	JJ	O
medium	NN	O
and	CC	O
removal	NN	O
of	IN	O
any	DT	O
one	CD	O
of	IN	O
these	DT	O
five	CD	O
factors	NNS	O
decreased	JJ	O
culture	NN	O
performance.	.	O
Some	DT	O
of	IN	O
these	DT	O
data	NNS	O
are	VBP	O
illustrated	VBN	O
in	IN	O
FIG.	.	O
6,	,	O
which	WDT	O
shows	VBZ	O
that	IN	O
cultures	NNS	O
grown	VBN	O
in	IN	O
media	NNS	O
with	IN	O
any	DT	O
one	CD	O
of	IN	O
these	DT	O
constituents	NNS	O
omitted	VBD	O
exhibited	VBD	O
a	DT	O
lesser	JJR	O
percentage	NN	O
of	IN	O
cells	NNS	O
which	WDT	O
remained	VBD	O
undifferentiated	JJ	O
as	IN	O
compared	VBN	O
to	TO	O
cultures	NNS	O
with	IN	O
all	DT	O
five	CD	O
of	IN	O
these	DT	O
medium	NN	O
constituents	NNS	O
included.	.	O
Note	NN	O
that	IN	O
Oct-4,	,	O
SSEA-1,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	NNS	O
are	VBP	O
all	DT	O
cell	NN	O
surface	NN	O
markers	NNS	O
or	CC	O
transcription	NN	O
factors	NNS	O
(Oct-4)	)	O
which	WDT	O
are	VBP	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
differentiation	NN	O
status	NN	O
of	IN	O
stem	NN	O
cells.	.	O
FIG.	.	O
4	CD	O
illustrates	NNS	O
similar	JJ	O
trials	NNS	O
in	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
demonstrated	VBN	O
that,	,	O
over	IN	O
multiple	JJ	O
passages,	,	O
undifferentiated	JJ	O
cell	NN	O
proliferation	NN	O
was	VBD	O
the	DT	O
highest	JJS	O
when	WRB	O
all	PDT	O
these	DT	O
constituents	NNS	O
together	RB	O
were	VBD	O
in	IN	O
the	DT	O
culture	NN	O
medium.	.	O
The	DT	O
inventors	NNS	O
also	RB	O
found	VBD	O
it	PRP	O
advantageous	JJ	O
to	TO	O
include	VB	O
in	IN	O
the	DT	O
culture	NN	O
vessel	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
a	DT	O
biological	JJ	O
matrix.	.	O
One	CD	O
such	JJ	O
material	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
used	VBN	O
previously	RB	O
is	VBZ	O
Matrigel™,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
artificial	JJ	O
basement	NN	O
matrix	NN	O
of	IN	O
mouse	NN	O
cell	NN	O
origin,	,	O
which	WDT	O
is	VBZ	O
supplied	VBN	O
as	IN	O
a	DT	O
commercial	JJ	O
product	NN	O
free	JJ	O
of	IN	O
mouse	NN	O
cells.	.	O
However,	,	O
the	DT	O
use	NN	O
of	IN	O
Matrigel	NNP	O
introduces	NNS	O
into	IN	O
the	DT	O
culture	NN	O
a	DT	O
material	NN	O
which	WDT	O
is	VBZ	O
poorly	RB	O
defined	VBN	O
and	CC	O
includes	VBZ	O
material	NN	O
of	IN	O
murine	NN	O
origin.	.	O
Accordingly,	,	O
also	RB	O
described	VBN	O
here	RB	O
is	VBZ	O
how	WRB	O
to	TO	O
create	VB	O
a	DT	O
biological	JJ	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
that	WDT	O
can	MD	O
substitute	VB	O
completely	RB	O
for	IN	O
the	DT	O
Matrigel.	.	O
This	DT	O
matrix	NN	O
is	VBZ	O
composed	VBN	O
of	IN	O
a	DT	O
blend	NN	O
of	IN	O
four	CD	O
human	JJ	O
proteins:	:	O
collagen	NN	O
isolated	VBD	O
from	IN	O
human	JJ	O
placenta,	,	O
fibronectin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma,	,	O
vitronectin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma	NN	O
or	CC	O
from	IN	O
a	DT	O
recombinant	JJ	O
source,	,	O
and	CC	O
laminin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
placenta.	.	O
Other	JJ	O
extracellular	JJ	O
matrices	NNS	O
may	MD	O
be	VB	O
suitable	JJ	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
present	JJ	O
invention,	,	O
which	WDT	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
proteoglycan,	,	O
entactin,	,	O
heparan	JJ	O
sulfate,	,	O
and	CC	O
the	DT	O
like,	,	O
alone	RB	O
or	CC	O
in	IN	O
various	JJ	O
combinations.	.	O
Other	JJ	O
suitable	JJ	O
extracellular	JJ	O
matrices	NNS	O
may	MD	O
include,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to,	,	O
Geltrex™.	.	O
The	DT	O
major	JJ	O
components	NNS	O
of	IN	O
Geltrex™	NNP	O
matrix	NNP	O
include	VBP	O
laminin,	,	O
collagen	NN	O
IV,	,	O
entactin,	,	O
and	CC	O
heparin	JJ	O
sulfate	NN	O
proteoglycan.	.	O
Also	RB	O
suitable	JJ	O
are	VBP	O
human	JJ	O
plasma	NN	O
fibronectin,	,	O
recombinant	JJ	O
human	JJ	O
plasma	NN	O
fibronectin,	,	O
human	JJ	O
cellular	JJ	O
fibronectin,	,	O
recombinant	JJ	O
human	JJ	O
cellular	JJ	O
fibronectin,	,	O
and	CC	O
synthetic	JJ	O
fibronectin	NN	O
in	IN	O
combination	NN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
other	JJ	O
matrix,	,	O
such	JJ	O
as	IN	O
collagen.	.	O
Preferred	NNP	O
matrices	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
collagen,	,	O
fibronectin,	,	O
vitronectin,	,	O
and	CC	O
laminin	VBZ	O
derived	VBN	O
matrices.	.	O
The	DT	O
combination	NN	O
of	IN	O
these	DT	O
four	CD	O
human	NN	O
proteins	NNS	O
is	VBZ	O
sufficient,	,	O
but	CC	O
the	DT	O
use	NN	O
of	IN	O
all	DT	O
four	CD	O
may	MD	O
not	RB	O
be	VB	O
necessary	JJ	O
to	TO	O
support	VB	O
the	DT	O
growth	NN	O
and	CC	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
the	DT	O
experimental	JJ	O
results	NNS	O
depicted	VBD	O
in	IN	O
FIG.	.	O
10.	.	O
For	IN	O
example,	,	O
the	DT	O
use	NN	O
of	IN	O
such	JJ	O
a	DT	O
matrix	NN	O
without	IN	O
one	CD	O
of	IN	O
vitronectin,	,	O
fibronectin,	,	O
or	CC	O
laminin,	,	O
but	CC	O
including	VBG	O
the	DT	O
other	JJ	O
three	CD	O
matrix	NN	O
proteins,	,	O
does	VBZ	O
support	VB	O
the	DT	O
culture	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
with	IN	O
some	DT	O
loss	NN	O
of	IN	O
purity	NN	O
in	IN	O
the	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
the	DT	O
ES	NNP	O
or	CC	O
iPS	NN	O
cell	NN	O
culture.	.	O
Likewise,	,	O
it	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
such	JJ	O
a	DT	O
matrix	NN	O
without	IN	O
two	CD	O
of	IN	O
vitronectin,	,	O
fibronectin	NN	O
or	CC	O
laminin,	,	O
does	VBZ	O
support	VB	O
the	DT	O
culture	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
with	IN	O
some	DT	O
loss	NN	O
of	IN	O
purity	NN	O
in	IN	O
the	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
the	DT	O
ES	NNP	O
or	CC	O
iPS	NN	O
cell	NN	O
culture.	.	O
Suitable	JJ	O
matrix	NN	O
protein	NN	O
combinations	NNS	O
include	VBP	O
collagen	NN	O
and	CC	O
fibronectin,	,	O
collagen	NN	O
and	CC	O
vitronectin,	,	O
and	CC	O
collagen	NN	O
and	CC	O
laminin.	.	O
The	DT	O
method	NN	O
of	IN	O
making	VBG	O
the	DT	O
matrix	NN	O
for	IN	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
growth	NN	O
is	VBZ	O
described	VBN	O
in	IN	O
the	DT	O
examples	NNS	O
below.	.	O
To	TO	O
arrive	VB	O
at	IN	O
the	DT	O
above-listed	JJ	O
medium	NN	O
additives,	,	O
the	DT	O
inventors	NNS	O
methodically	RB	O
tested	VBD	O
over	IN	O
80	CD	O
individual	JJ	O
media	NNS	O
components,	,	O
including	VBG	O
growth	NN	O
factors.	.	O
While	IN	O
some	DT	O
of	IN	O
the	DT	O
additives	NNS	O
seemed,	,	O
at	IN	O
least	JJS	O
for	IN	O
a	DT	O
few	JJ	O
passages,	,	O
to	TO	O
support	VB	O
the	DT	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture,	,	O
many	JJ	O
failed	VBD	O
in	IN	O
subsequent	JJ	O
passages	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state.	.	O
The	DT	O
inventors	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
identify	VB	O
combinations	NNS	O
of	IN	O
specific	JJ	O
growth	NN	O
factors	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
medium	NN	O
described	VBN	O
in	IN	O
the	DT	O
examples	NNS	O
below.	.	O
Also,	,	O
through	IN	O
methodical	JJ	O
testing,	,	O
the	DT	O
inventors	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
varying	VBG	O
the	DT	O
concentration	NN	O
of	IN	O
β-mercaptoethanol	NNP	O
(BME)	)	O
in	IN	O
the	DT	O
TeSR1	NNP	O
medium,	,	O
when	WRB	O
culturing	VBG	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
BME	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
various	JJ	O
parameters	NNS	O
in	IN	O
a	DT	O
culture	NN	O
medium	NN	O
that	WDT	O
affects	VBZ	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
pluripotent	NN	O
cells	NNS	O
in	IN	O
a	DT	O
positive	JJ	O
manner.	.	O
Specifically,	,	O
when	WRB	O
BME	NNP	O
was	VBD	O
either	RB	O
omitted	VBN	O
or	CC	O
used	VBN	O
in	IN	O
a	DT	O
concentration	NN	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
(between	IN	O
about	RB	O
0	CD	O
to	TO	O
about	IN	O
0.1	CD	O
mM)	)	O
in	IN	O
the	DT	O
TeSR1	NNP	O
medium,	,	O
the	DT	O
cells	NNS	O
continued	VBD	O
to	TO	O
proliferate	VB	O
(see	VB	O
FIG.	.	O
15	CD	O
a-b)	)	O
with	IN	O
minimal	JJ	O
to	TO	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
differentiation	NN	O
status	NN	O
of	IN	O
the	DT	O
cells	NNS	O
(see	VB	O
FIG.	.	O
15	CD	O
c).	.	O
Most	JJS	O
notably,	,	O
however,	,	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10%	NN	O
and	CC	O
preferably	RB	O
20%,	,	O
30%,	,	O
40%,	,	O
50%,	,	O
60%,	,	O
70%,	,	O
80%,	,	O
90%,	,	O
and	CC	O
100%	NN	O
(see	VB	O
FIG.	.	O
15	CD	O
a)	)	O
in	IN	O
comparison	NN	O
with	IN	O
pluripotent	JJ	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium	NN	O
having	VBG	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
BME.	.	O
Accordingly,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention,	,	O
a	DT	O
medium	NN	O
is	VBZ	O
disclosed	VBN	O
for	IN	O
increasing	VBG	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
pluripotent	NN	O
cells	NNS	O
in	IN	O
culture,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
contains	VBZ	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid,	,	O
and	CC	O
lithium,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages,	,	O
wherein	VBP	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
increases	VBZ	O
by	IN	O
at	IN	O
least	JJS	O
10%	NN	O
compared	VBN	O
to	TO	O
the	DT	O
medium	NN	O
containing	VBG	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.1	CD	O
mM	NN	O
BME.	.	O
In	IN	O
another	DT	O
embodiment,	,	O
a	DT	O
method	NN	O
is	VBZ	O
disclosed	VBN	O
for	IN	O
increasing	VBG	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
cells	NNS	O
in	IN	O
culture	NN	O
by	IN	O
at	IN	O
least	JJS	O
10%	NN	O
through	IN	O
culturing	VBG	O
the	DT	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media,	,	O
the	DT	O
medium	NN	O
comprising	NN	O
salts,	,	O
vitamins,	,	O
amino	JJ	O
acids,	,	O
glucose,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid,	,	O
and	CC	O
lithium	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages.	.	O
In	IN	O
a	DT	O
related	JJ	O
embodiment,	,	O
when	WRB	O
gamma-aminobutyric	JJ	O
acid,	,	O
pipecolic	JJ	O
acid,	,	O
lithium,	,	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
are	VBP	O
added	VBN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state,	,	O
at	IN	O
least	JJS	O
90%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages.	.	O
In	IN	O
general,	,	O
the	DT	O
observation	NN	O
that	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
have	VBP	O
previously	RB	O
been	VBN	O
maintained	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
only	RB	O
when	WRB	O
cultured	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
in	IN	O
conditioned	JJ	O
medium	NN	O
has	VBZ	O
led	VBN	O
to	TO	O
speculation	NN	O
that	IN	O
the	DT	O
fibroblasts	NNS	O
release	VBP	O
a	DT	O
factor	NN	O
into	IN	O
the	DT	O
medium,	,	O
which	WDT	O
acts	VBZ	O
to	TO	O
inhibit	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
differentiation.	.	O
The	DT	O
data	NN	O
presented	VBD	O
here	RB	O
demonstrate	VB	O
that	IN	O
this	DT	O
not	RB	O
the	DT	O
case.	.	O
However,	,	O
whatever	WDT	O
effect	NN	O
fibroblast	NN	O
feeder	NN	O
cells	NNS	O
have	VBP	O
on	IN	O
culture	NN	O
medium,	,	O
it	PRP	O
is	VBZ	O
now	RB	O
clear	JJ	O
that	IN	O
the	DT	O
media	NNS	O
described	VBN	O
below	IN	O
will	MD	O
substitute	VB	O
for	IN	O
that	DT	O
effect.	.	O
The	DT	O
media	NNS	O
described	VBD	O
below,	,	O
as	IN	O
defined,	,	O
contain	VBP	O
no	DT	O
non-human	JJ	O
cells,	,	O
and	CC	O
permit	VB	O
the	DT	O
long-term	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells.	.	O
This	DT	O
strategy	NN	O
enables	VBZ	O
the	DT	O
preparation	NN	O
of	IN	O
a	DT	O
“humanized”	JJ	O
medium	NN	O
and	CC	O
matrix	NN	O
to	TO	O
avoid	VB	O
any	DT	O
possible	JJ	O
concerns	NNS	O
about	IN	O
sub-cellular	JJ	O
products	NNS	O
of	IN	O
non-human	JJ	O
origin.	.	O
Table	JJ	O
1	CD	O
describes	VBZ	O
a	DT	O
defined	JJ	O
medium	NN	O
developed	VBN	O
by	IN	O
the	DT	O
inventors.	.	O
All	DT	O
of	IN	O
the	DT	O
medium	NN	O
components	NNS	O
and	CC	O
their	PRP$	O
preferred	JJ	O
concentrations	NNS	O
are	VBP	O
listed	VBN	O
in	IN	O
the	DT	O
table.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
concentration	NN	O
ranges	VBZ	O
that	WDT	O
are	VBP	O
at	IN	O
least	JJS	O
10×	CD	O
higher	JJR	O
or	CC	O
10×	CD	O
lower	JJR	O
than	IN	O
the	DT	O
concentrations	NNS	O
listed	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
may	MD	O
be	VB	O
able	JJ	O
to	TO	O
support	VB	O
culture	NN	O
and	CC	O
derivation	NN	O
of	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells.	.	O
The	DT	O
complete	JJ	O
medium	NN	O
is	VBZ	O
designated	VBN	O
TeSR1.	.	O
The	DT	O
TeSR1	NNP	O
medium	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
DMEM/DF12	NNP	O
base,	,	O
supplemented	VBN	O
with	IN	O
human	JJ	O
serum	NN	O
albumin,	,	O
vitamins,	,	O
antioxidants,	,	O
trace	NN	O
minerals,	,	O
specific	JJ	O
lipids	NNS	O
and	CC	O
cloned	JJ	O
growth	NN	O
factors.	.	O
Based	VBN	O
on	IN	O
the	DT	O
formulation	NN	O
of	IN	O
TeSR1	NNP	O
in	IN	O
Table	NNP	O
1,	,	O
it	PRP	O
is	VBZ	O
expected	VBN	O
that	IN	O
a	DT	O
suitable	JJ	O
concentration	NN	O
range	NN	O
for	IN	O
a	DT	O
salt	NN	O
in	IN	O
the	DT	O
medium	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
100	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
vitamin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-05	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.5	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
an	DT	O
amino	NN	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-03	JJ	O
mM	NN	O
to	TO	O
about	IN	O
30	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
mineral	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-07	JJ	O
mM	NN	O
to	TO	O
about	IN	O
10.0	CD	O
E-02	JJ	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
lipid	JJ	O
is	VBZ	O
from	IN	O
about	IN	O
8.0	CD	O
E-06	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-02	JJ	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
glucose	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
mM	NNS	O
to	TO	O
about	IN	O
150	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
ng/ml	NNS	O
to	TO	O
about	IN	O
1000	CD	O
ng/ml.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
10	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
pipecolic	JJ	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-04	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-02	JJ	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
lithium	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
10	CD	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
transforming	JJ	O
growth	NN	O
factor	NN	O
beta	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-09	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.0	CD	O
E-07	JJ	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
insulin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
4.0	CD	O
E-04	JJ	O
mM	NN	O
to	TO	O
about	IN	O
4.0	CD	O
E-02	JJ	O
mM.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
transferrin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-05	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-03	JJ	O
mM.	.	O
Also,	,	O
a	DT	O
suitable	JJ	O
concentration	NN	O
range	NN	O
for	IN	O
albumin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
2.0	CD	O
E-02	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.0	CD	O
mM.	.	O
Because	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
(HSA)	)	O
is	VBZ	O
expensive,	,	O
the	DT	O
inventors	NNS	O
routinely	RB	O
use	VBP	O
bovine	JJ	O
serum	NN	O
albumin	NN	O
(BSA)	)	O
as	IN	O
a	DT	O
less	RBR	O
costly	JJ	O
substitute.	.	O
Although	IN	O
the	DT	O
species	NNS	O
source	NN	O
of	IN	O
the	DT	O
albumin	NN	O
is	VBZ	O
different,	,	O
BSA	NNP	O
in	IN	O
the	DT	O
TeSR	NNP	O
medium	NN	O
(mTeSR1)	)	O
functions	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
its	PRP$	O
humanized	JJ	O
counterpart,	,	O
TeSR1	NNP	O
medium,	,	O
which	WDT	O
contains	VBZ	O
HSA.	.	O
This	DT	O
humanized	JJ	O
version	NN	O
of	IN	O
TeSR	NNP	O
has	VBZ	O
been	VBN	O
renamed	VBN	O
and	CC	O
is	VBZ	O
currently	RB	O
marketed	VBN	O
as	IN	O
TeSR2	NNP	O
by	IN	O
Stem	NNP	O
Cell	NNP	O
Technologies	NNPS	O
(Vancouver,	,	O
BC,	,	O
Canada).	.	O
Also	RB	O
described	VBN	O
below	IN	O
is	VBZ	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
using	VBG	O
TeSR1	NNP	O
(see	VB	O
Ludwig	NNP	B
T.	NNP	I
E.	NNP	I
et	FW	I
al.	.	I
Nat.	.	I
Biotech.	.	I
24(2),	,	I
185-187	JJ	I
(2006)	)	I
and	CC	O
related	JJ	O
Supplementary	NNP	O
results,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety).	.	O
The	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines,	,	O
such	JJ	O
as	IN	O
ES	NNP	O
and	CC	O
iPS	JJ	O
cells,	,	O
disclosed	VBN	O
herein	NN	O
and	CC	O
provided	VBN	O
in	IN	O
the	DT	O
corresponding	JJ	O
Ludwig	NNP	O
(2006)	)	O
paper	NN	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells,	,	O
conditioned	VBD	O
medium,	,	O
non-human	JJ	O
animal	NN	O
products	NNS	O
or	CC	O
non-human	JJ	O
animal	JJ	O
proteins.	.	O
It	PRP	O
has	VBZ	O
previously	RB	O
been	VBN	O
reported	VBN	O
that	IN	O
prior	JJ	O
human	JJ	O
ES	NNP	O
lines	NNS	O
exhibit	VBP	O
a	DT	O
sialic	JJ	O
acid	NN	O
form	NN	O
(Neu5Gc)	)	O
that	WDT	O
is	VBZ	O
not	RB	O
natively	RB	O
found	VBN	O
in	IN	O
human	JJ	O
cells	NNS	O
whether	IN	O
in	IN	O
culture	NN	O
or	CC	O
in	IN	O
the	DT	O
body.	.	O
Since	IN	O
the	DT	O
prior	JJ	O
human	JJ	O
ES	NNP	O
lines	NNS	O
acquired	VBD	O
the	DT	O
Neu5Gc	NNP	O
from	IN	O
culture	NN	O
conditions	NNS	O
including	VBG	O
murine	NN	O
components,	,	O
the	DT	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
described	VBN	O
here	RB	O
are	VBP	O
and	CC	O
will	MD	O
be	VB	O
entirely	RB	O
free	JJ	O
of	IN	O
Neu5Gc	NNP	O
(FIG.	.	O
12).	.	O
The	DT	O
invention	NN	O
will	MD	O
be	VB	O
more	RBR	O
fully	RB	O
understood	JJ	O
upon	IN	O
consideration	NN	O
of	IN	O
the	DT	O
following	JJ	O
non-limiting	JJ	O
Examples.	.	O
In	IN	O
the	DT	O
Examples,	,	O
pluripotent	JJ	O
stem	NN	O
cells,	,	O
including	VBG	O
human	JJ	O
ES	NNP	O
cells	NNS	O
and	CC	O
iPS	JJ	O
cells,	,	O
were	VBD	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
(set	VBN	O
forth	NN	O
in	IN	O
Table	JJ	O
1	CD	O
below)	)	O
and	CC	O
variations	NNS	O
of	IN	O
the	DT	O
medium	NN	O
where	WRB	O
certain	JJ	O
components	NNS	O
have	VBP	O
been	VBN	O
removed.	.	O
It	PRP	O
is	VBZ	O
specifically	RB	O
contemplated	VBN	O
that	IN	O
the	DT	O
methods	NNS	O
disclosed	VBN	O
are	VBP	O
suited	VBN	O
for	IN	O
primate	JJ	O
pluripotent	NN	O
cells	NNS	O
generally	RB	O
as	IN	O
pluripotent	NN	O
cells,	,	O
regardless	RB	O
of	IN	O
their	PRP$	O
origin,	,	O
operate	NN	O
in	IN	O
substantially	RB	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
the	DT	O
disclosed	JJ	O
methods.	.	O
Accordingly,	,	O
the	DT	O
media	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
here	RB	O
are	VBP	O
suitable	JJ	O
for	IN	O
culturing	VBG	O
primate	JJ	O
iPS	NN	O
cells.	.	O
EXAMPLES	NNP	O
Inventors	NNS	O
used	VBD	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
H1,	,	O
H7,	,	O
H9	NNP	O
and	CC	O
H14	NNP	O
Thomson,	,	B
J.	.	I
A.	NN	I
et	CC	I
al.	.	I
Science	NN	I
282,	,	I
1145-1147	CD	I
(1998))	)	I
(in	IN	O
a	DT	O
program	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
media	NNS	O
optimization	NN	O
that	WDT	O
included	VBD	O
modifications	NNS	O
to	TO	O
the	DT	O
physiochemical	JJ	O
environment,	,	O
growth	NN	O
factor	NN	O
supplements	NNS	O
and	CC	O
matrix	JJ	O
components.	.	O
To	TO	O
accomplish	VB	O
this,	,	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
H1,	,	O
H7,	,	O
H9,	,	O
and	CC	O
H14	NNP	O
were	VBD	O
cultured	VBN	O
on	IN	O
Matrigel	NNP	O
(Becton	NNP	O
Dickinson)	)	O
in	IN	O
fibroblast-conditioned	JJ	O
medium	NN	O
as	IN	O
previously	RB	O
described	VBN	O
Xu,	,	B
C.	NNP	I
et	CC	I
al.	.	I
Nature	NNP	I
Biotechnology	NNP	I
19,	,	I
971-974	CD	I
(2001)).(	.	O
Cells	NNS	O
were	VBD	O
transitioned	VBN	O
into	IN	O
test	NN	O
media	NNS	O
by	IN	O
direct	JJ	O
passage	NN	O
from	IN	O
conditioned	VBN	O
medium.	.	O
Cultures	NNS	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
in	IN	O
clumps	NNS	O
at	IN	O
approximately	RB	O
weekly	JJ	O
intervals	NNS	O
onto	IN	O
Matrigel	NNP	O
or	CC	O
human	JJ	O
matrix-coated	JJ	O
plates	NNS	O
by	IN	O
exposure	NN	O
to	TO	O
dispase	VB	O
(2.0	CD	O
or	CC	O
0.5	CD	O
mg/ml	NNS	O
respectively:	:	O
Invitrogen).	.	O
Following	VBG	O
7	CD	O
minutes	NNS	O
of	IN	O
dispase	NN	O
exposure,	,	O
cells	NNS	O
were	VBD	O
rinsed	VBN	O
3	CD	O
(three)	)	O
times	NNS	O
on	IN	O
the	DT	O
plate	NN	O
with	IN	O
medium,	,	O
followed	VBN	O
by	IN	O
gentle	JJ	O
scraping	VBG	O
to	TO	O
collect.	.	O
Colonies	NNS	O
were	VBD	O
further	RB	O
broken	VBN	O
up	RP	O
by	IN	O
gentle	JJ	O
pipetting	NN	O
and	CC	O
then	RB	O
plated.	.	O
The	DT	O
human	JJ	O
matrix-coated	JJ	O
plates	NNS	O
were	VBD	O
composed	VBN	O
of	IN	O
10	CD	O
μg/cm2	JJ	O
human	JJ	O
collagen	NN	O
IV	NNP	O
(Sigma	NNP	O
or	CC	O
Becton	NNP	O
Dickinson),	,	O
0.2	CD	O
μg/cm2	JJ	O
human	JJ	O
vitronectin	NN	O
(Sigma),	,	O
5	CD	O
μg/cm2	JJ	O
human	JJ	O
fibronectin	NN	O
(Sigma	NNP	O
or	CC	O
Becton	NNP	O
Dickinson)	)	O
and	CC	O
5	CD	O
μg/cm2	JJ	O
human	JJ	O
laminin	NN	O
(Sigma).	.	O
During	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
studies	NNS	O
we	PRP	O
successfully	RB	O
used	VBD	O
4	CD	O
lots	NNS	O
of	IN	O
fibronectin,	,	O
2	CD	O
lots	NNS	O
of	IN	O
collagen,	,	O
3	CD	O
lots	NNS	O
of	IN	O
laminin,	,	O
and	CC	O
3	CD	O
lots	NNS	O
of	IN	O
vitronectin.	.	O
For	IN	O
growth	NN	O
curve	NN	O
proliferation	NN	O
studies,	,	O
3-5×105	JJ	O
cells	NNS	O
were	VBD	O
plated	VBN	O
on	IN	O
Day	NNP	O
0	CD	O
of	IN	O
each	DT	O
passage	NN	O
into	IN	O
conditioned	JJ	O
medium,	,	O
TeSR1	NNP	O
or	CC	O
TeSR1	NNP	O
minus	CC	O
the	DT	O
following	JJ	O
components:	:	O
TGFβ,	,	O
PA,	,	O
GABA,	,	O
LiCl	NNP	O
and	CC	O
bFGF.	.	O
Cells	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
three	CD	O
passages.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
on	IN	O
Day	NNP	O
2-3	JJ	O
and	CC	O
Day	NNP	O
6-7	JJ	O
and	CC	O
counted	VBD	O
using	VBG	O
a	DT	O
Trypan	NNP	O
Blue	NNP	O
exclusion	NN	O
assay.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
passage	NN	O
three,	,	O
cells	NNS	O
were	VBD	O
individualized	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
trypsin/EDTA	NN	O
and	CC	O
were	VBD	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
markers	NNS	O
Oct-4,	,	O
SSEA-4,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
as	IN	O
subsequently	RB	O
described.	.	O
Specifically,	,	O
to	TO	O
optimize	VB	O
the	DT	O
physiochemical	JJ	O
environment,	,	O
human	JJ	O
ES	NNP	O
cells	NNS	O
with	IN	O
an	DT	O
EGFP	NNP	O
reporter	NN	O
gene	NN	O
and	CC	O
a	DT	O
neomycin	JJ	O
resistance	NN	O
cassette	NN	O
under	IN	O
control	NN	O
of	IN	O
the	DT	O
endogenous	JJ	O
Oct-4	JJ	O
gene	NN	O
were	VBD	O
utilized	VBN	O
for	IN	O
the	DT	O
physiochemical	JJ	O
optimization	NN	O
assays.	.	O
Cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
G418	NNP	O
(Invitrogen)	)	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
assay	NN	O
to	TO	O
ensure	VB	O
a	DT	O
pure	JJ	O
stem	NN	O
cell	NN	O
population	NN	O
upon	IN	O
initiation.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
growth	NN	O
period,	,	O
cells	NNS	O
from	IN	O
independent	JJ	O
wells	NNS	O
were	VBD	O
individualized	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
trypsin/EDTA,	,	O
counted	VBN	O
and	CC	O
subjected	VBN	O
to	TO	O
FACS	NNP	O
analysis	NN	O
as	IN	O
subsequently	RB	O
described.	.	O
To	TO	O
determine	VB	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells,	,	O
resulting	VBG	O
colonies	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
BCIP/NTB	NNP	O
alkaline	JJ	O
phosphatase	NN	O
substrate	JJ	O
kit	NN	O
IV	NNP	O
(Vector	NNP	O
Laboratories)	)	O
and	CC	O
counted.	.	O
Percentages	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
dividing	VBG	O
colony	NN	O
number	NN	O
obtained	VBN	O
by	IN	O
the	DT	O
initial	JJ	O
number	NN	O
of	IN	O
cells	NNS	O
plated.	.	O
Our	PRP$	O
analysis	NN	O
of	IN	O
physiochemical	JJ	O
culture	NN	O
conditions	NNS	O
suggested	VBD	O
that	IN	O
undifferentiated	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
proliferation	NN	O
was	VBD	O
optimal	JJ	O
at	IN	O
a	DT	O
pH	NN	O
of	IN	O
7.2,	,	O
an	DT	O
osmolarity	NN	O
of	IN	O
350	CD	O
mOsMol	NN	O
and	CC	O
an	DT	O
atmosphere	NN	O
of	IN	O
10%	NN	O
CO2/5%	NN	O
O2	NNP	O
(FIG.	.	O
1).	.	O
These	DT	O
conditions	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
all	DT	O
subsequent	JJ	O
cultures	NNS	O
described	VBD	O
herein.	.	O
An	DT	O
initial	JJ	O
subjective	JJ	O
list	NN	O
of	IN	O
growth	NN	O
factors	NNS	O
was	VBD	O
selected	VBN	O
for	IN	O
testing	VBG	O
based	VBN	O
on	IN	O
receptors	NNS	O
expressed	VBN	O
by	IN	O
human	JJ	O
ES	NNP	O
cells.	.	O
(See	VB	O
Sperger,	,	B
J.	NNP	I
M.	NNP	I
et	FW	I
al.	.	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	.	I
USA	NNP	I
100,	,	I
13350-13355	CD	I
(2003)).Several	.	O
were	JJ	O
found	VBD	O
to	VBN	O
have	TO	O
a	VB	O
positive	DT	O
effect	JJ	O
on	NN	O
undifferentiated	IN	O
proliferation.	JJ	O
Of	.	O
these,	IN	O
bFGF,	,	O
LiCl,	,	O
GABA,	,	O
PA	,	O
and	NNP	O
TGFβ	CC	O
were	NNP	O
ultimately	VBD	O
included	RB	O
in	VBN	O
TeSR1.	IN	O
To	.	O
test	TO	O
the	VB	O
conditions	DT	O
of	NNS	O
the	IN	O
ES	DT	O
cell	NNP	O
colonies	NN	O
and	NNS	O
the	CC	O
suitability	DT	O
of	NN	O
the	IN	O
culture	DT	O
for	NN	O
the	IN	O
long-term	DT	O
maintenance	JJ	O
of	NN	O
human	IN	O
ES	JJ	O
cell	NNP	O
cultures,	NN	O
the	,	O
TeSR1	DT	O
medium	NNP	O
was	NN	O
compared	VBD	O
to	VBN	O
the	TO	O
best	DT	O
prior	JJS	O
medium	JJ	O
condition,	NN	O
which,	,	O
in	,	O
the	IN	O
inventor's	DT	O
hands,	POS	O
is	,	O
the	VBZ	O
use	DT	O
of	NN	O
conditioned	IN	O
medium.	JJ	O
It	.	O
was	PRP	O
found	VBD	O
that	VBN	O
the	IN	O
TeSR1	DT	O
medium	NNP	O
was	NN	O
capable	VBD	O
of	JJ	O
increasing	IN	O
cellular	VBG	O
proliferation	JJ	O
(FIG.	NN	O
2)	.	O
and	)	O
maintaining	CC	O
the	VBG	O
human	DT	O
ES	JJ	O
cells	NNP	O
in	NNS	O
such	IN	O
an	JJ	O
undifferentiated	DT	O
state	JJ	O
that	NN	O
over	WDT	O
90%	IN	O
of	NN	O
the	IN	O
cells	DT	O
continued	NNS	O
to	VBD	O
test	TO	O
positive	VB	O
for	JJ	O
Oct-4	IN	O
even	NNP	O
after	RB	O
long-term	IN	O
culture	JJ	O
(FIG.	NN	O
3).	.	O
This	.	O
represents	DT	O
the	VBZ	O
first	DT	O
known	JJ	O
instance	VBN	O
in	NN	O
which	IN	O
any	WDT	O
medium,	DT	O
free	,	O
of	JJ	O
both	IN	O
feeder	DT	O
cells	NN	O
and	NNS	O
conditioned	CC	O
medium,	JJ	O
has	,	O
maintained	VBZ	O
undifferentiated	VBN	O
growth	JJ	O
of	NN	O
human	IN	O
pluripotent	JJ	O
stem	JJ	O
cells	NN	O
such	NNS	O
that	JJ	O
over	IN	O
90%	IN	O
of	NN	O
the	IN	O
cells	DT	O
in	NNS	O
the	IN	O
culture	DT	O
remain	NN	O
undifferentiated.	NN	O
Using	.	O
the	VBG	O
media	DT	O
and	NNS	O
culture	CC	O
system	NN	O
described	NN	O
here,	VBD	O
it	,	O
is	PRP	O
now	VBZ	O
possible	RB	O
to	JJ	O
establish	TO	O
and	VB	O
maintain	CC	O
primate	VB	O
pluripotent	JJ	O
stem	JJ	O
cell	NN	O
lines	NN	O
that	NNS	O
comprise	WDT	O
at	VBP	O
least	IN	O
70%,	JJS	O
at	,	O
least	IN	O
80%,	JJS	O
more	,	O
preferably	JJR	O
at	RB	O
least	IN	O
85	JJS	O
to	CD	O
89%,	TO	O
more	,	O
preferably	JJR	O
at	RB	O
least	IN	O
90%,	JJS	O
and	,	O
most	CC	O
preferably	JJS	O
at	RB	O
least	IN	O
91	JJS	O
to	CD	O
99%	TO	O
undifferentiated	NN	O
stem	JJ	O
cells.	NN	O
Several	.	O
factors	JJ	O
were	NNS	O
found	VBD	O
to	VBN	O
have	TO	O
a	VB	O
positive	DT	O
effect	JJ	O
on	NN	O
undifferentiated	IN	O
proliferation.	JJ	O
Of	.	O
these,	IN	O
bFGF,	,	O
LiCl,	,	O
GABA,	,	O
PA,	,	O
and	,	O
TGFβ	CC	O
were	NNP	O
ultimately	VBD	O
included	RB	O
in	VBN	O
TeSR1.	IN	O
Removal	.	O
of	NN	O
any	IN	O
one	DT	O
of	CD	O
the	IN	O
five	DT	O
factors	CD	O
significantly	NNS	O
decreased	RB	O
some	VBD	O
parameter	DT	O
of	NN	O
culture	IN	O
performance,	NN	O
but	,	O
only	CC	O
the	RB	O
removal	DT	O
of	NN	O
bFGF	IN	O
consistently	NN	O
decreased	RB	O
both	VBN	O
the	CC	O
total	DT	O
cell	NN	O
number	NN	O
and	NN	O
the	CC	O
percentage	DT	O
of	NN	O
cells	IN	O
expressing	NNS	O
ES	VBG	O
cell	NNP	O
markers	NN	O
(FIGS.	NNS	O
2,	.	O
4	,	O
and	CD	O
6).	CC	O
When	.	O
exogenous	WRB	O
bFGF	JJ	O
was	NN	O
removed,	VBD	O
some	,	O
undifferentiated	DT	O
cells	JJ	O
nonetheless	NNS	O
persisted	RB	O
through	VBD	O
at	IN	O
least	IN	O
three	JJS	O
passages	CD	O
(FIGS.	NNS	O
2,	.	O
4	,	O
and	CD	O
6).	CC	O
If	.	O
all	IN	O
five	DT	O
factors	CD	O
were	NNS	O
removed,	VBD	O
however,	,	O
culture	,	O
was	NN	O
not	VBD	O
sustainable	RB	O
beyond	JJ	O
the	IN	O
first	DT	O
passage	JJ	O
(FIGS.	NN	O
2,	.	O
4	,	O
and	CD	O
6).	CC	O
While	.	O
a	IN	O
medium	DT	O
with	NN	O
all	IN	O
of	DT	O
the	IN	O
above	DT	O
constituents	JJ	O
is	NNS	O
sufficient	VBZ	O
and	JJ	O
is	CC	O
preferred,	VBZ	O
not	,	O
all	RB	O
of	DT	O
the	IN	O
components	DT	O
are	NNS	O
necessary	VBP	O
for	JJ	O
the	IN	O
successful	DT	O
culture	JJ	O
of	NN	O
human	IN	O
pluripotent	JJ	O
stem	JJ	O
cells.	NN	O
Depending	.	O
on	VBG	O
the	IN	O
amount	DT	O
of	NN	O
differentiated	IN	O
cells	JJ	O
one	NNS	O
is	CD	O
willing	VBZ	O
to	JJ	O
tolerate,	TO	O
some	,	O
of	DT	O
the	IN	O
components	DT	O
of	NNS	O
the	IN	O
medium	DT	O
can	NN	O
be	MD	O
omitted,	VB	O
particularly	,	O
if	RB	O
the	IN	O
medium	DT	O
is	NN	O
only	VBZ	O
used	RB	O
for	VBN	O
a	IN	O
few	DT	O
passages.	JJ	O
To	.	O
further	TO	O
explore	RBR	O
which	RB	O
constituents	WDT	O
might	NNS	O
be	MD	O
omitted,	VB	O
human	,	O
pluripotent	JJ	O
stem	NN	O
cells	NN	O
were	NNS	O
cultured	VBD	O
on	VBN	O
variants	IN	O
of	NNS	O
the	IN	O
above	DT	O
medium	JJ	O
with	NN	O
differing	IN	O
components	VBG	O
omitted.	NNS	O
Two	.	O
hundred	CD	O
thousand	CD	O
cells	NNS	O
were	NNS	O
plated	VBD	O
and	VBN	O
grown	CC	O
for	VBN	O
seven	IN	O
days	CD	O
on	NNS	O
each	IN	O
experimental	DT	O
medium,	JJ	O
two	,	O
wells	CD	O
per	NNS	O
treatment.	IN	O
The	.	O
cells	DT	O
were	NNS	O
then	VBD	O
assayed	RB	O
for	VBN	O
expression	IN	O
of	NN	O
the	IN	O
transcription	DT	O
factor	NN	O
Oct-4,	NN	O
a	,	O
recognized	DT	O
marker	VBN	O
of	NN	O
undifferentiated	IN	O
cells.	JJ	O
The	.	O
data	DT	O
from	NN	O
that	IN	O
experiment	DT	O
are	NN	O
presented	VBP	O
graphically	VBN	O
in	RB	O
FIG.	IN	O
7,	.	O
where	,	O
the	WRB	O
numbers	DT	O
of	NNS	O
Oct-4	IN	O
expressing	NNP	O
cells	VBG	O
in	NNS	O
each	IN	O
experimental	DT	O
medium	JJ	O
are	NN	O
presented	VBP	O
as	VBN	O
a	IN	O
fraction	DT	O
of	NN	O
that	IN	O
from	DT	O
the	IN	O
preferred	DT	O
medium	JJ	O
TeSR1.	NN	O
Note	.	O
that	NN	O
TGFβ	IN	O
seems	NNP	O
to	VBZ	O
be	TO	O
the	VB	O
least	DT	O
necessary	JJS	O
component,	JJ	O
at	,	O
least	IN	O
in	JJS	O
the	IN	O
presence	DT	O
of	NN	O
high	IN	O
levels	JJ	O
of	NNS	O
FGF	IN	O
for	NNP	O
short-term	IN	O
culture.	JJ	O
Also,	.	O
note	,	O
that	NN	O
omitting	IN	O
other	VBG	O
constituents	JJ	O
(e.g.,	NNS	O
LiCl,	,	O
bFGF,	,	O
PA,	,	O
or	,	O
GABA)	CC	O
does	)	O
result	VBZ	O
in	VB	O
increased	IN	O
percentages	JJ	O
of	NNS	O
undifferentiated	IN	O
cells	JJ	O
in	NNS	O
the	IN	O
culture.	DT	O
The	.	O
difference	DT	O
between	NN	O
the	IN	O
percentage	DT	O
of	NN	O
undifferentiated	IN	O
cells	JJ	O
and	NNS	O
the	CC	O
omitted	DT	O
constituent	JJ	O
is	NN	O
quantitative.	VBZ	O
Regardless	.	O
of	RB	O
the	IN	O
omitted	DT	O
constituent,	JJ	O
the	,	O
medium	DT	O
does	NN	O
work,	VBZ	O
at	,	O
least	IN	O
to	JJS	O
some	TO	O
degree	DT	O
for	NN	O
limited	IN	O
cell	JJ	O
passages,	NN	O
without	,	O
each	IN	O
of	DT	O
the	IN	O
omitted	DT	O
components.	JJ	O
Cells	.	O
of	NNS	O
human	IN	O
ES	JJ	O
cell	NNP	O
lines	NN	O
H1,	NNS	O
H7,	,	O
H9	,	O
and	NNP	O
H14	CC	O
cells	NNP	O
have	NNS	O
all	VBP	O
proliferated	DT	O
robustly	VBN	O
in	RB	O
TeSR1	IN	O
for	NNP	O
11,	IN	O
7,	,	O
25,	,	O
and	,	O
17	CC	O
passages	CD	O
respectively	NNS	O
(2-6	RB	O
months).	JJ	O
The	.	O
karyotypes	DT	O
were	NNS	O
confirmed	VBD	O
normal	VBN	O
for	JJ	O
cell	IN	O
line	NN	O
H14	NN	O
after	NNP	O
7	IN	O
passages	CD	O
and	NNS	O
H9	CC	O
after	NNP	O
8	IN	O
and	CD	O
21	CC	O
passages	CD	O
(FIG.	NNS	O
8).	.	O
Teratoma	.	O
formation	NNP	O
was	NN	O
confirmed	VBD	O
for	VBN	O
H1	IN	O
and	NNP	O
H9	CC	O
after	NNP	O
11	IN	O
and	CD	O
20	CC	O
passages,	CD	O
respectively	,	O
(FIG.	RB	O
9).	.	O
Initial	.	O
experiments	JJ	O
with	NNS	O
TeSR1	IN	O
medium	NNP	O
were	NN	O
all	VBD	O
performed	DT	O
on	VBN	O
Matrigel,	IN	O
a	,	O
basement	DT	O
membrane	NN	O
preparation	NN	O
extracted	NN	O
from	VBD	O
a	IN	O
murine	DT	O
Englebreth-Holm-Swarm	JJ	O
sarcoma.	JJ	O
Matrigel	.	O
effectively	NNP	O
supports	RB	O
long-term	VBZ	O
proliferation	JJ	O
of	NN	O
human	IN	O
pluripotent	JJ	O
stem	JJ	O
cells	NN	O
in	NNS	O
TeSR1	IN	O
medium,	NNP	O
but	,	O
it	CC	O
is	PRP	O
a	VBZ	O
complex	DT	O
mixture	JJ	O
of	NN	O
murine	IN	O
proteins	NN	O
and	NNS	O
is	CC	O
a	VBZ	O
significant	DT	O
source	JJ	O
of	NN	O
variability	IN	O
in	NN	O
culture.	IN	O
After	.	O
screening	IN	O
a	VBG	O
variety	DT	O
of	NN	O
components	IN	O
individually	NNS	O
and	RB	O
in	CC	O
combination,	IN	O
the	,	O
inventors	DT	O
developed	NNS	O
a	VBD	O
new	DT	O
matrix	JJ	O
material	JJ	O
of	NN	O
human	IN	O
origin	JJ	O
composed	NN	O
of	VBN	O
the	IN	O
following	DT	O
four	VBG	O
proteins:	CD	O
1.	:	O
Collagen	.	O
(isolated	NNP	O
from	VBN	O
human	IN	O
placenta)	JJ	O
at	)	O
a	IN	O
final	DT	O
concentration	JJ	O
of	NN	O
10	IN	O
μg/100	CD	O
μl/cm2.	JJ	O
2.	.	O
Fibronectin	.	O
(isolated	NNP	O
from	VBN	O
human	IN	O
plasma)	JJ	O
at	)	O
a	IN	O
final	DT	O
concentration	JJ	O
of	NN	O
5	IN	O
μg/100	CD	O
μl/cm2.	JJ	O
3.	.	O
Vitronectin	.	O
(isolated	NNP	O
from	VBN	O
human	IN	O
plasma)	JJ	O
at	)	O
a	IN	O
final	DT	O
concentration	JJ	O
of	NN	O
0.2	IN	O
μg/100	CD	O
μl/cm2.	JJ	O
4.	.	O
Laminin	.	O
(isolated	NNP	O
from	VBN	O
human	IN	O
placenta)	JJ	O
at	)	O
a	IN	O
final	DT	O
concentration	JJ	O
of	NN	O
μg/100	IN	O
μl/cm2.	NNP	O
To	.	O
assemble	TO	O
this	VB	O
matrix,	DT	O
the	,	O
collagen	DT	O
is	NN	O
denatured	VBZ	O
with	VBN	O
6M	IN	O
GuHCl	CD	O
(guanidine	NNP	O
HCl),	JJ	O
filtered	,	O
through	VBN	O
a	IN	O
0.45	DT	O
micron	CD	O
filter	NN	O
and	NN	O
frozen	CC	O
in	NN	O
aliquots.	IN	O
Upon	.	O
thaw,	IN	O
denatured	,	O
collagen	VBD	O
was	NN	O
diluted	VBD	O
into	VBN	O
Ca-	IN	O
and	NNP	O
Mg-free	CC	O
phosphate	NNP	O
buffered	NN	O
saline	VBD	O
(PBS),	NN	O
to	,	O
achieve	TO	O
the	VB	O
appropriate	DT	O
final	JJ	O
concentration	JJ	O
and	NN	O
was	CC	O
then	VBD	O
plated.	RB	O
The	.	O
coated	DT	O
plates	JJ	O
were	NNS	O
allowed	VBD	O
to	VBN	O
incubate	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
no	IN	O
less	DT	O
than	JJR	O
1	IN	O
hour	CD	O
before	NN	O
the	IN	O
additional	DT	O
matrix	JJ	O
components	NN	O
were	NNS	O
plated.	VBD	O
Following	.	O
this	VBG	O
initial	DT	O
incubation,	JJ	O
additional	,	O
matrix	JJ	O
components	NN	O
(fibronectin,	NNS	O
vitronectin	,	O
and	NN	O
laminin)	CC	O
were	)	O
diluted	VBD	O
into	VBN	O
a	IN	O
Ca-	DT	O
and	JJ	O
Mg-free	CC	O
PBS	JJ	O
to	NNP	O
achieve	TO	O
the	VB	O
appropriate	DT	O
final	JJ	O
concentration	JJ	O
and	NN	O
plated.	CC	O
The	.	O
coated	DT	O
plates	JJ	O
were	NNS	O
allowed	VBD	O
to	VBN	O
incubate	TO	O
at	VB	O
room	IN	O
temperature	NN	O
for	NN	O
no	IN	O
less	DT	O
than	JJR	O
1	IN	O
hour	CD	O
before	NN	O
human	IN	O
pluripotent	JJ	O
stem	NN	O
cells,	NN	O
such	,	O
as	JJ	O
ES	IN	O
and	NNP	O
iPS	CC	O
cells)	VB	O
were	)	O
plated.	VBD	O
The	.	O
combination	DT	O
of	NN	O
four	IN	O
human	CD	O
proteins	JJ	O
was	NNS	O
found	VBD	O
to	VBN	O
support	TO	O
robust,	VB	O
long-term	,	O
proliferation	JJ	O
of	NN	O
human	IN	O
pluripotent	JJ	O
stem	JJ	O
cells	NN	O
in	NNS	O
TeSR1.	IN	O
Using	.	O
the	VBG	O
new	DT	O
matrix	JJ	O
material,	NN	O
human	,	O
pluripotent	JJ	O
stem	NN	O
cells	NN	O
of	NNS	O
previously	IN	O
existing	RB	O
lines	VBG	O
have	NNS	O
been	VBP	O
cultured	VBN	O
for	VBN	O
a	IN	O
minimum	DT	O
of	NN	O
10	IN	O
passages	CD	O
while	NNS	O
remaining	IN	O
undifferentiated	VBG	O
and	JJ	O
proliferating.	CC	O
Specifically,	.	O
cell	,	O
lines	NN	O
H1	NNS	O
and	NNP	O
H9,	CC	O
cultured	,	O
in	VBD	O
TeSR1	IN	O
on	NNP	O
the	IN	O
human	DT	O
matrix	JJ	O
for	NN	O
11	IN	O
and	CD	O
16	CC	O
passages,	CD	O
respectively,	,	O
continued	,	O
to	VBD	O
express	TO	O
markers	VB	O
characteristic	NNS	O
of	JJ	O
human	IN	O
ES	JJ	O
cells	NNP	O
(FIG.	NNS	O
11).	.	O
Human	.	O
ES	NNP	O
cells	NNP	O
cultured	NNS	O
for	VBD	O
5	IN	O
passages	CD	O
in	NNS	O
TeSR1	IN	O
on	NNP	O
human	IN	O
matrix	JJ	O
continued	NN	O
to	VBD	O
show	TO	O
morphology	VB	O
characteristics	JJ	O
of	NNS	O
ES	IN	O
cells,	NNP	O
and	,	O
to	CC	O
express	TO	O
markers	VB	O
characteristic	NNS	O
of	JJ	O
ES	IN	O
cells	NNP	O
(FIG.	NNS	O
11).	.	O
Analyses	.	O
for	NNS	O
internal	IN	O
(Oct-4)	JJ	O
or	)	O
cell	CC	O
surface	NN	O
(SSEA4,	NN	O
Tra	,	O
1-60,	NNP	O
Tra	,	O
1-81)	NNP	O
markers	)	O
after	NNS	O
11	IN	O
passages	CD	O
of	NNS	O
culture	IN	O
in	NN	O
TeSR1	IN	O
on	NNP	O
human	IN	O
matrix	JJ	O
components	NN	O
(FIG.	NNS	O
11	.	O
d-g)	CD	O
were	)	O
all	VBD	O
greater	DT	O
than	JJR	O
90%	IN	O
percent	NN	O
positive.	NN	O
To	.	O
test	TO	O
the	VB	O
strict	DT	O
necessity	JJ	O
for	NN	O
the	IN	O
components	DT	O
of	NNS	O
the	IN	O
humanized	DT	O
matrix,	JJ	O
variations	,	O
on	NNS	O
the	IN	O
matrix	DT	O
were	NN	O
formulated	VBD	O
with	VBN	O
one	IN	O
or	CD	O
more	CC	O
components	JJR	O
omitted.	NNS	O
The	.	O
data	DT	O
from	NN	O
that	IN	O
experiment	DT	O
is	NN	O
presented	VBZ	O
in	VBN	O
FIG.	IN	O
10.	.	O
Note	.	O
that	NN	O
CFV,	IN	O
CVL	,	O
and	NNP	O
CFL	CC	O
matrices	NNP	O
do	NNS	O
work	VBP	O
well	VB	O
and	RB	O
maintain	CC	O
human	VB	O
pluripotent	JJ	O
stem	JJ	O
cells,	NN	O
such	,	O
as	JJ	O
ES	IN	O
and	NNP	O
iPS	CC	O
cells,	JJ	O
in	,	O
an	IN	O
undifferentiated	DT	O
state.	JJ	O
Also,	.	O
as	,	O
described	IN	O
above,	VBN	O
it	,	O
is	PRP	O
envisioned	VBZ	O
that	VBN	O
CV,	IN	O
CF,	,	O
and	,	O
CL	CC	O
could	NNP	O
also	MD	O
maintain	RB	O
cell	VB	O
growth	NN	O
and	NN	O
prevent	CC	O
differentiation.	NN	O
Morphological	.	O
assessment	JJ	O
and	NN	O
visual	CC	O
observations	JJ	O
of	NNS	O
attachment	IN	O
suggest	JJ	O
that	NN	O
using	IN	O
only	VBG	O
two	RB	O
components	CD	O
of	NNS	O
the	IN	O
humanized	DT	O
matrix	JJ	O
one	NN	O
can	CD	O
achieve	MD	O
attachment,	VB	O
although	,	O
at	IN	O
a	IN	O
lower	DT	O
rate	JJR	O
than	NN	O
with	IN	O
three	IN	O
or	CD	O
four	CC	O
components.	CD	O
The	.	O
CVFL	DT	O
matrix	NNP	O
is	NN	O
simply	VBZ	O
more	RB	O
conducive	RBR	O
to	JJ	O
cell	TO	O
culture	VB	O
growth.	NN	O
Generally,	.	O
CVFL	,	O
matrices	NNP	O
provide	NNS	O
greater	VBP	O
attachment	JJR	O
than	NN	O
CFV,	IN	O
CVL,	,	O
or	,	O
CFL	CC	O
matrices,	NNP	O
which	,	O
in	WDT	O
turn	IN	O
provide	NN	O
greater	VBP	O
attachment	JJR	O
than	NN	O
CF,	IN	O
CL,	,	O
or	,	O
CV	CC	O
matrices	NNP	O
(these	NNS	O
observations	DT	O
represent	NNS	O
three	VBP	O
replicates;	CD	O
data	:	O
not	NNS	O
shown).	RB	O
TeSR1	.	O
as	NNP	O
defined	IN	O
in	VBN	O
Table	IN	O
1	JJ	O
includes	CD	O
BME	VBZ	O
(i.e.,	NNP	O
2-mercaptothanol).	,	O
Generally,	.	O
it	,	O
is	PRP	O
known	VBZ	O
that	VBN	O
BME	IN	O
reduces	NNP	O
disulfide	NNS	O
bonds	JJ	O
and	NNS	O
acts	CC	O
as	NNS	O
an	IN	O
antioxidant	DT	O
by	NN	O
scavenging	IN	O
hydroxyl	VBG	O
radicals.	JJ	O
When	.	O
BME	WRB	O
is	NNP	O
added	VBZ	O
to	VBN	O
cell	TO	O
culture	VB	O
medium	NN	O
it	NN	O
is	PRP	O
generally	VBZ	O
believed	RB	O
to	VBN	O
reduce	TO	O
the	VB	O
oxidative	DT	O
stress	JJ	O
on	NN	O
cells	IN	O
in	NNS	O
culture.	IN	O
To	.	O
test	TO	O
the	VB	O
strict	DT	O
necessity	JJ	O
for	NN	O
BME	IN	O
in	NNP	O
TeSR1,	IN	O
we	,	O
tested	PRP	O
5	VBD	O
doses	CD	O
of	NNS	O
BME	IN	O
in	NNP	O
modified	IN	O
TeSR1:	JJ	O
0,	:	O
1.75,	,	O
3.5,	,	O
7,	,	O
and	,	O
14	CC	O
μL	CD	O
BME/500	NN	O
mL	NNP	O
of	NN	O
total	IN	O
media	JJ	O
(FIG.	NNS	O
15).	.	O
Based	.	O
on	VBN	O
cell	IN	O
counts	NN	O
and	NNS	O
pluripotency,	CC	O
0	,	O
and	CD	O
1.75	CC	O
μL	CD	O
BME/500	NN	O
mL	NNP	O
of	NN	O
total	IN	O
media	JJ	O
yielded	NNS	O
large	VBD	O
increases	JJ	O
in	NNS	O
cloning	IN	O
efficiency	VBG	O
of	NN	O
the	IN	O
cells	DT	O
(FIG.	NNS	O
15	.	O
b).	CD	O
These	.	O
data	DT	O
confirm	NNS	O
that	VBP	O
it	IN	O
is	PRP	O
feasible	VBZ	O
and	JJ	O
in	CC	O
some	IN	O
instances	DT	O
advantageous	NNS	O
to	JJ	O
culture	TO	O
pluripotent	NN	O
stem	NN	O
cells	NN	O
in	NNS	O
TeSR1	IN	O
in	NNP	O
the	IN	O
absence	DT	O
of	NN	O
BME.	IN	O
To	.	O
confirm	TO	O
that	VB	O
the	IN	O
TeSR1	DT	O
medium	NNP	O
supports	NN	O
culture	VBZ	O
of	NN	O
non-embryonic	IN	O
pluripotent	JJ	O
stem	JJ	O
cells	NN	O
in	NNS	O
an	IN	O
undifferentiated	DT	O
state,	JJ	O
two	,	O
iPS	CD	O
cells	NN	O
lines	NNS	O
were	NNS	O
cultured	VBD	O
in	VBN	O
modified	IN	O
TeSR1	JJ	O
(FIG.	NNP	O
16).	.	O
The	.	O
iPS	DT	O
cell	NN	O
line	NN	O
IMR90	NN	O
Yu	NNP	B
et	NNP	I
al.,	RB	I
Science	,	I
2007;	NNP	I
(and	:	O
provided	CC	O
by	VBN	O
WISC	IN	O
Bank)	NNP	O
was	)	O
cultured	VBD	O
for	VBN	O
at	IN	O
least	IN	O
10	JJS	O
passages	CD	O
in	NNS	O
mTeSR1.	IN	O
Through	.	O
10	IN	O
passages	CD	O
IMR90	NNS	O
maintained	NNP	O
greater	VBD	O
than	JJR	O
95%	IN	O
Oct-4	NN	O
positive	NNP	O
cells	JJ	O
(FIG.	NNS	O
16	.	O
a).	CD	O
The	.	O
vector-free	DT	O
iPS	JJ	O
cell	NN	O
line	NN	O
iPS-DF-19-9	NN	O
(Yu	NN	O
et	NNP	O
al.,	RB	O
2009	,	O
Science;	CD	O
also	:	O
provided	RB	O
by	VBN	O
WISC	IN	O
Bank)	NNP	O
was	)	O
cultured	VBD	O
for	VBN	O
at	IN	O
least	IN	O
16	JJS	O
passages	CD	O
in	NNS	O
mTeSR1.	IN	O
iPS-DF-19-9	.	O
maintained	NN	O
more	VBD	O
than	JJR	O
98%	IN	O
Oct-4	NN	O
positive	NNP	O
cells,	JJ	O
through	,	O
16	IN	O
passages	CD	O
(FIG.	NNS	O
16B).	.	O
Recently,	.	O
other	,	O
research	JJ	O
groups	NN	O
have	NNS	O
also	VBP	O
confirmed	RB	O
that	VBN	O
the	IN	O
TeSR1	DT	O
medium	NNP	O
supports	NN	O
cell	NNS	O
culture,	NN	O
maintenance	,	O
and	NN	O
derivation	CC	O
of	NN	O
iPS	IN	O
cells.	NN	O
For	.	O
example,	IN	O
Sun	,	O
N,	NNP	O
et	,	O
al.	RB	O
reports	.	O
the	NNS	O
feeder-free	DT	O
derivation	JJ	O
of	NN	O
induced	IN	O
pluripotent	JJ	O
stem	JJ	O
cells	NN	O
from	NNS	O
adult	IN	O
human	NN	O
adipose	JJ	O
stem	JJ	O
cells	NN	O
with	NNS	O
mTeSR1	IN	O
hES	JJ	O
growth	NN	O
medium	NN	O
available	NN	O
through	JJ	O
StemCell	IN	O
Technologies	NNP	O
located	NNPS	O
in	VBN	O
Vancouver,	IN	O
BC,	,	O
Canada.	,	O
Sun	.	B
N,	NNP	I
et	,	I
al.	RB	I
PNAS	.	I
106(37),	$	I
15720-15725	,	I
(2009),	JJ	I
(incorporated	,	O
by	VBN	O
reference	IN	O
here	NN	O
in	RB	O
its	IN	O
entirety).	PRP$	O
Likewise,	.	O
Chan	,	O
E	NNP	O
M,	NNP	O
et	,	O
al.	RB	O
have	.	O
used	VBP	O
mTeSR1	VBN	O
medium	NN	O
to	NN	O
derive	TO	O
fully	VB	O
reprogrammed	RB	O
iPS	VBN	O
cells	JJ	O
on	NNS	O
Matrigel™	IN	O
and	NNP	O
shown	CC	O
that	VBN	O
live	IN	O
cell	JJ	O
imaging	NN	O
can	VBG	O
distinguish	MD	O
bona	VB	O
fide	JJ	O
human	JJ	O
iPS	JJ	O
cells	NN	O
from	NNS	O
partially	IN	O
reprogrammed	RB	O
cells	VBN	O
Chan	NNS	B
et	NNP	I
al.	RB	I
Nat.	.	I
Biotech	.	I
2009	NN	I
Nov.	CD	I
27(11):1033-7,	NNP	I
(incorporated	,	O
by	VBN	O
reference	IN	O
here	NN	O
in	RB	O
its	IN	O
entirety).	PRP$	O
Collectively,	.	O
these	,	O
results	DT	O
indicate	NNS	O
that	VBP	O
the	IN	O
TeSR1	DT	O
defined	NNP	O
medium	VBD	O
can	NN	O
support	MD	O
cell	VB	O
culture	NN	O
maintenance	NN	O
and	NN	O
derivation	CC	O
of	NN	O
pluripotent	IN	O
stem	JJ	O
cells	NN	O
derived	NNS	O
from	VBN	O
somatic	IN	O
cells.	JJ	O
As	.	O
described	IN	O
above,	VBN	O
mTeSR1	,	O
and	NN	O
the	CC	O
original	DT	O
TeSR1	JJ	O
have	NNP	O
the	VBP	O
same	DT	O
function	JJ	O
and	NN	O
are	CC	O
chemically	VBP	O
similar.	RB	O
The	.	O
main	DT	O
difference	JJ	O
is	NN	O
that	VBZ	O
TeSR1	IN	O
medium	NNP	O
contains	NN	O
HSA,	VBZ	O
which	,	O
is	WDT	O
very	VBZ	O
expensive,	RB	O
and	,	O
the	CC	O
mTeSR	DT	O
medium	NN	O
contains	NN	O
bovine	VBZ	O
serum	JJ	O
albumin	NN	O
(BSA),	NN	O
which	,	O
is	WDT	O
more	VBZ	O
commercially	RBR	O
economical.	RB	O
Because	.	O
HSA	IN	O
is	NNP	O
expensive	VBZ	O
to	JJ	O
obtain,	TO	O
the	,	O
inventors	DT	O
routinely	NNS	O
use	RB	O
BSA	VBP	O
as	NNP	O
a	IN	O
less	DT	O
costly	RBR	O
substitute.	JJ	O
Although	.	O
the	IN	O
species	DT	O
source	NNS	O
of	NN	O
the	IN	O
albumin	DT	O
is	NN	O
different,	VBZ	O
BSA	,	O
in	NNP	O
the	IN	O
TeSR	DT	O
medium	NNP	O
(mTeSR1)	NN	O
functions	)	O
the	VBZ	O
same	DT	O
as	JJ	O
its	IN	O
humanized	PRP$	O
counterpart,	JJ	O
TeSR1	,	O
medium,	NNP	O
which	,	O
contains	WDT	O
HSA.	VBZ	O
It	.	O
is	PRP	O
important	VBZ	O
to	JJ	O
note	TO	O
that	VB	O
this	IN	O
humanized	DT	O
version	JJ	O
of	NN	O
TeSR	IN	O
has	NNP	O
been	VBZ	O
renamed	VBN	O
and	VBN	O
is	CC	O
currently	VBZ	O
marketed	RB	O
as	VBN	O
TeSR2	IN	O
by	NNP	O
Stem	IN	O
Cell	NNP	O
Technologies	NNP	O
(Vancouver,	NNPS	O
BC,	,	O
Canada).	,	O
It	.	O
has	PRP	O
been	VBZ	O
suggested	VBN	O
that	VBN	O
prior	IN	O
ES	JJ	O
cell	NNP	O
cultures	NN	O
are	NNS	O
less	VBP	O
than	JJR	O
optimal	IN	O
because	JJ	O
of	IN	O
the	IN	O
presence	DT	O
of	NN	O
Neu5Gc,	IN	O
a	,	O
sialic	DT	O
acid	JJ	O
not	NN	O
made	RB	O
by	VBN	O
humans,	IN	O
contaminating	,	O
human	VBG	O
ES	JJ	O
cells.	NNP	O
Accordingly,	.	O
to	,	O
determine	TO	O
whether	VB	O
Neu5Gc	IN	O
could	NNP	O
be	MD	O
eliminated	VB	O
from	VBN	O
existing	IN	O
human	VBG	O
ES	JJ	O
cell	NNP	O
lines,	NN	O
H9	,	O
cells	NNP	O
were	NNS	O
grown	VBD	O
under	VBN	O
three	IN	O
different	CD	O
conditions,	JJ	O
1)	,	O
conditioned	)	O
medium	VBD	O
on	NN	O
Matrigel,	IN	O
42	,	O
passages	CD	O
2)	NNS	O
TeSR1	)	O
on	NN	O
Matrigel,	IN	O
16	,	O
passages	CD	O
and	NNS	O
3)	CC	O
TeSR1	)	O
on	NN	O
human	IN	O
matrix,	JJ	O
5	,	O
passages.	CD	O
Approximately	.	O
2×107	RB	O
cells	CD	O
from	NNS	O
each	IN	O
condition	DT	O
were	NN	O
collected	VBD	O
and	VBN	O
purified	CC	O
for	VBN	O
analysis	IN	O
employing	NN	O
methods	VBG	O
similar	NNS	O
to	JJ	O
those	TO	O
described	DT	O
previously	VBN	O
(see	RB	O
Bardor,	VB	B
M.	,	I
et	NNP	I
al.	CC	I
J	.	I
Biol	NNP	I
Chem	NNP	I
280,	NNP	I
4228-4237;	,	I
2005).The	:	O
purified	.	O
sialic	DT	O
acids	JJ	O
were	JJ	O
derivatized	NNS	O
with	VBD	O
DMB	VBN	O
(1,2-diamino-4,5-methylenedioxybenzene	IN	O
dihydrochloride)	NNP	O
(Dojindo)	JJ	O
to	)	O
take	)	O
advantage	TO	O
of	VB	O
previously	NN	O
described	IN	O
detection	RB	O
methods	VBN	O
via	NN	O
liquid	NNS	O
chromatography-mass	IN	O
spectrometry	JJ	O
(LC-MS).	NN	O
The	NN	O
inventors	.	O
employed	DT	O
a	NNS	O
Surveyor	VBD	O
HPLC	DT	O
in-line	NNP	O
with	NNP	O
a	NN	O
LCQ	IN	O
DECA	DT	O
XP	NNP	O
Plus	NNP	O
ion	NNP	O
trap	NNP	O
mass	NN	O
spectrometer	NN	O
(ThermoElectron).	NN	O
The	NN	O
Genesis	.	O
C18,	DT	O
120	NNP	O
angstrom,	,	O
4	CD	O
micron	,	O
particle	CD	O
size	NN	O
(Grace	NN	O
Vydac)	NN	O
column	NNP	O
was	)	O
packed	NN	O
in-house	VBD	O
(250	VBN	O
micron	NN	O
by	CD	O
100	NN	O
mm).	IN	O
Sample	CD	O
elution	.	O
was	JJ	O
carried	NN	O
out	VBD	O
by	VBN	O
ramping	RP	O
a	IN	O
linear	VBG	O
gradient	DT	O
from	JJ	O
14%	NN	O
to	IN	O
20%	NN	O
organic	TO	O
(acetonitrile:methanol)	NN	O
in	JJ	O
0.1%	)	O
aqueous	IN	O
formic	NN	O
acid	JJ	O
over	JJ	O
10	NN	O
minutes	IN	O
at	CD	O
a	NNS	O
flow	IN	O
rate	DT	O
of	JJ	O
1	NN	O
μl/min	IN	O
(all	CD	O
solvents:	NNS	O
Burdick	DT	O
&	:	O
Jackson:	NNP	O
High	CC	O
Purity).	:	O
Electrospray	NNP	O
voltage	.	O
of	NNP	O
3300V,	NN	O
175°	IN	O
C.	,	O
capillary	CD	O
temperature	NNP	O
and	JJ	O
a	NN	O
nitrogen	CC	O
sheath	DT	O
gas	JJ	O
of	NN	O
15	NN	O
psi	IN	O
were	CD	O
employed.	NNS	O
Data	VBD	O
acquisition	.	O
was	NNP	O
set	NN	O
for	VBD	O
a	VBN	O
full	IN	O
scan	DT	O
MS	JJ	O
followed	JJ	O
by	NNP	O
two	VBN	O
sequential	IN	O
MS/MS	CD	O
acquisitions	JJ	O
for	NNP	O
the	NNS	O
parent	IN	O
masses	DT	O
of	NN	O
the	NNS	O
Neu5Ac	IN	O
and	DT	O
Neu5Gc	NNP	O
(426	CC	O
and	NNP	O
442	CD	O
m/z)	CC	O
derivatized	CD	O
products.	)	O
Reconstructed	VBN	O
ion	.	O
chromatograms	VBN	O
were	NN	O
plotted	NNS	O
for	VBD	O
the	VBN	O
principle	IN	O
MS/MS	DT	O
daughter	NN	O
ions	NNP	O
for	NN	O
Neu5Ac	NNS	O
and	IN	O
Neu5Gc	NNP	O
at	CC	O
408	NNP	O
m/z	IN	O
and	CD	O
424	NN	O
m/z	CC	O
respectively.	CD	O
Conditions	NN	O
for	.	O
derivatization	NNS	O
and	IN	O
LC-MS	NN	O
analysis	CC	O
were	JJ	O
established	NN	O
using	VBD	O
commercially	VBN	O
purchased	VBG	O
standards	RB	O
of	VBN	O
Neu5Ac	NNS	O
and	IN	O
Neu5Gc	NNP	O
(Sigma-Aldrich).	CC	O
The	NNP	O
inventors	.	O
found	DT	O
that	NNS	O
Neu5Gc	VBD	O
was	IN	O
present	NNP	O
on	VBD	O
human	JJ	O
ES	IN	O
cells	JJ	O
cultured	NNP	O
in	NNS	O
fibroblast	VBN	O
conditioned	IN	O
medium.	NN	O
A	JJ	O
reduced	.	O
but	DT	O
detectable	VBN	O
amount	CC	O
of	JJ	O
Neu5Gc	NN	O
was	IN	O
found	NNP	O
on	VBD	O
cells	VBN	O
cultured	IN	O
in	NNS	O
TeSR1	VBN	O
on	IN	O
Matrigel.	NNP	O
However,	IN	O
no	.	O
Neu5Gc	,	O
was	DT	O
detected	NNP	O
on	VBD	O
ES	VBN	O
cells	IN	O
cultured	NNP	O
in	NNS	O
TeSR1	VBN	O
using	IN	O
the	NNP	O
four	VBG	O
human	DT	O
matrix	CD	O
components.	JJ	O
These	NN	O
data	.	O
are	DT	O
illustrated	NNS	O
in	VBP	O
FIG.	VBN	O
12.	IN	O
Thus,	.	O
human	.	O
pluripotent	,	O
stem	JJ	O
cells	NN	O
cultured	NN	O
on	NNS	O
TeSR1	VBN	O
and	IN	O
on	NNP	O
a	CC	O
matrix	IN	O
of	DT	O
human	NN	O
proteins	IN	O
do	JJ	O
not	NNS	O
exhibit	VBP	O
the	RB	O
non-human	VB	O
sialic	DT	O
acid	JJ	O
residues	JJ	O
found	NN	O
on	NNS	O
cells	VBN	O
cultured	IN	O
on	NNS	O
murine	VBN	O
feeder	IN	O
cells.	NN	O
This	NN	O
medium	.	O
has	DT	O
also	NN	O
proven	VBZ	O
capable	RB	O
of	VBN	O
supporting	JJ	O
the	IN	O
initiation	VBG	O
of	DT	O
new	NN	O
lines	IN	O
of	JJ	O
human	NNS	O
pluripotent	IN	O
stem	JJ	O
cells.	JJ	O
The	NN	O
derivation	.	O
process	DT	O
for	NN	O
new	NN	O
lines	IN	O
can	JJ	O
be	NNS	O
a	MD	O
difficult	VB	O
test	DT	O
for	JJ	O
medium	NN	O
formulations,	IN	O
but	NN	O
the	,	O
use	CC	O
of	DT	O
the	NN	O
defined	IN	O
medium	DT	O
makes	JJ	O
it	NN	O
possible	VBZ	O
to	PRP	O
create	JJ	O
new	TO	O
lines	VB	O
of	JJ	O
human	NNS	O
pluripotent	IN	O
stem	JJ	O
cells	JJ	O
which	NN	O
have	NNS	O
not	WDT	O
been	VBP	O
exposed	RB	O
to	VBN	O
non-human	VBN	O
animal	TO	O
proteins	JJ	O
or	JJ	O
matrices,	NNS	O
and	CC	O
have	,	O
never	CC	O
been	VBP	O
exposed	RB	O
to	VBN	O
feeder	VBN	O
cells	TO	O
or	VB	O
medium	NNS	O
in	CC	O
which	NN	O
feeder	IN	O
cells	WDT	O
were	NN	O
cultured.	NNS	O
This	VBD	O
is	.	O
believed	DT	O
to	VBZ	O
be	VBN	O
a	TO	O
novel	VB	O
and	DT	O
unexpected	JJ	O
achievement.	CC	O
This	JJ	O
work	.	O
was	DT	O
undertaken	NN	O
only	VBD	O
after	VBN	O
obtaining	RB	O
institutional	IN	O
review	VBG	O
board	JJ	O
approval	NN	O
and	NN	O
informed	NN	O
consent	CC	O
from	JJ	O
donors	NN	O
(HSC	IN	O
Protocol	NNS	O
#2000-434).	NNP	O
Frozen	NNP	O
human	.	O
pre-embryos	NNP	O
that	JJ	O
were	NN	O
fertilized	WDT	O
for	VBD	O
fertility	VBN	O
treatment	IN	O
but	NN	O
were	NN	O
in	CC	O
excess	VBD	O
of	IN	O
clinic	NN	O
need	IN	O
were	JJ	O
thawed	NN	O
for	VBD	O
the	VBN	O
purpose	IN	O
of	DT	O
deriving	NN	O
new	IN	O
human	VBG	O
pluripotent	JJ	O
stem	JJ	O
cell	NN	O
lines.	NN	O
Using	NN	O
commercially	.	O
available	VBG	O
sequential	RB	O
embryo	JJ	O
culture	JJ	O
media	NN	O
(Vitrolife-GIII	NN	O
Series)	NNS	O
supplemented	NNP	O
with	)	O
5%	VBD	O
Serum	IN	O
Protein	NN	O
Substitute	NNP	O
(SPS:	NNP	O
Cooper	NNP	O
Surgical),	:	O
the	NNP	O
frozen/thawed	,	O
embryos	DT	O
were	VBN	O
cultured	NN	O
for	VBD	O
seven	VBN	O
days	IN	O
in	CD	O
10	NNS	O
μL	IN	O
drops	CD	O
under	JJ	O
oil	NNS	O
at	IN	O
37°	NN	O
C.	IN	O
and	CD	O
5%	NNP	O
O2/10%	CC	O
CO2/85%	NN	O
N2.	NN	O
After	NN	O
removal	.	O
of	IN	O
the	NN	O
zona	IN	O
pellucida	DT	O
with	NN	O
pronase,	NN	O
the	IN	O
inner	,	O
cell	DT	O
mass	NN	O
(ICM)	NN	O
of	NN	O
five	)	O
human	IN	O
blastocysts	CD	O
were	JJ	O
isolated	NNS	O
by	VBD	O
immunosurgery	VBN	O
Solter	IN	B
and	NN	I
Knowles,	NNP	I
1975,	CC	I
Proc.	,	I
Natl.	,	I
Acad.	.	I
Sci.	.	I
USA,	.	I
72:5099-5102)	.	I
(or	,	O
as	)	O
cultured	CC	O
whole	IN	O
mounts	JJ	O
Evans	JJ	B
and	NNS	I
Kaufman,	NNPS	I
1981,	CC	I
Nature,	,	I
292154-156)	,	I
(and	,	O
plated	)	O
in	CC	O
4-well	VBN	O
culture	IN	O
plates	JJ	O
(Nunc)	NN	O
onto	NNS	O
the	)	O
defined	IN	O
medium	DT	O
TeSR1	JJ	O
with	NN	O
the	NNP	O
defined	IN	O
humanized	DT	O
matrix,	JJ	O
CVFL,	JJ	O
as	,	O
described	,	O
above.	IN	O
Following	VBN	O
an	.	O
initial	VBG	O
48	DT	O
hours	JJ	O
of	CD	O
culture,	NNS	O
the	IN	O
culture	,	O
medium	DT	O
(TeSR1)	NN	O
was	NN	O
replaced	)	O
on	VBD	O
a	VBN	O
daily	IN	O
basis.	DT	O
After	JJ	O
14	.	O
to	IN	O
21	CD	O
days,	TO	O
clumps	CD	O
of	,	O
cells	NNS	O
were	IN	O
mechanically	NNS	O
isolated	VBD	O
and	RB	O
replated	JJ	O
onto	CC	O
fresh	JJ	O
human	IN	O
matrix.	JJ	O
Mechanical	JJ	O
isolation	.	O
was	JJ	O
continued	NN	O
for	VBD	O
the	VBN	O
subsequent	IN	O
2	DT	O
to	JJ	O
3	CD	O
passages	TO	O
after	CD	O
which	NNS	O
colonies	IN	O
were	WDT	O
passaged	NNS	O
using	VBD	O
0.5	VBN	O
mg/ml	VBG	O
dispase	CD	O
(Invitrogen).	JJ	O
The	NN	O
new	.	O
colonies	DT	O
were	JJ	O
confirmed	NNS	O
to	VBD	O
be	VBN	O
new	TO	O
lines	VB	O
of	JJ	O
human	NNS	O
pluripotent	IN	O
stem	JJ	O
cells	JJ	O
using	NN	O
standard	NNS	O
cell	VBG	O
line	JJ	O
characterization	NN	O
techniques.	NN	O
Using	NN	O
TeSR1	.	O
medium	VBG	O
on	NNP	O
the	NN	O
four	IN	O
human	DT	O
matrix	CD	O
components,	JJ	O
CVFL,	NN	O
two	,	O
new	,	O
human	CD	O
ES	JJ	O
cell	JJ	O
lines	NNP	O
(WA15	NN	O
and	NNS	O
WA16;	NNP	O
FIG.	CC	O
13)	:	O
were	.	O
derived	)	O
from	VBD	O
5	VBN	O
cultured	IN	O
blastocysts.	CD	O
Both	JJ	O
human	.	O
ES	DT	O
cell	JJ	O
lines	NNP	O
have	NN	O
now	NNS	O
been	VBP	O
continuously	RB	O
in	VBN	O
culture	RB	O
for	IN	O
more	NN	O
than	IN	O
7	JJR	O
months.	IN	O
Analysis	CD	O
of	.	O
these	NN	O
lines	IN	O
by	DT	O
fluorescence-activated	NNS	O
cell	IN	O
sorting	JJ	O
(FACS)	NN	O
and	VBG	O
RT-PCR	)	O
demonstrated	CC	O
that	NNP	O
they	VBD	O
express	IN	O
markers	PRP	O
characteristic	VBP	O
of	NNS	O
human	JJ	O
ES	IN	O
cells	JJ	O
(FIG.	NNP	O
13),	NNS	O
and	.	O
both	,	O
cell	CC	O
lines	DT	O
formed	NN	O
teratomas	NNS	O
when	VBN	O
injected	NN	O
into	WRB	O
severe	VBN	O
combined	IN	O
immunodeficient-beige	JJ	O
mice.	VBN	O
FACS	JJ	O
analysis	.	O
was	NNP	O
performed	NN	O
by	VBD	O
first	VBN	O
removing	IN	O
the	JJ	O
cells	VBG	O
from	DT	O
the	NNS	O
culture	IN	O
dish	DT	O
with	NN	O
Trypsin/EDTA	NN	O
(Invitrogen)	IN	O
containing	NNP	O
2%	)	O
chick	VBG	O
serum	NN	O
(ICN)	NN	O
for	NN	O
10	)	O
minutes	IN	O
at	CD	O
37°	NNS	O
C.	IN	O
and	CD	O
resuspended	NNP	O
in	CC	O
1	VBD	O
ml	IN	O
fluorescence	CD	O
activated	NNS	O
cell	RB	O
sorting	VBD	O
(FACS)	NN	O
buffer	NN	O
[PBS	)	O
−/−	VBP	O
(Invitrogen)	NNP	O
containing	NNP	O
0.1%	)	O
sodium	VBG	O
azide	NN	O
(Sigma)	NN	O
and	NN	O
2%	)	O
fetal	CC	O
bovine	NN	O
serum	JJ	O
(Gibco)].	NN	O
Cells	NN	O
to	.	O
be	NNS	O
probed	TO	O
for	VB	O
the	VBN	O
internal	IN	O
marker	DT	O
Oct-4	JJ	O
were	NN	O
fixed	NNP	O
with	VBD	O
0.1%	VBN	O
paraformaldehyde	IN	O
(Electron	NN	O
Microscopy	NN	O
Sciences)	NNP	O
for	NNP	O
10	)	O
min.	IN	O
at	CD	O
37°	.	O
C.	IN	O
then	CD	O
permeabilized	NNP	O
with	RB	O
90%	VBD	O
methanol	IN	O
(Fisher	NN	O
Scientific)	NN	O
for	NNP	O
30	)	O
min	IN	O
on	CD	O
ice.	NN	O
1-5×105	IN	O
fixed	.	O
(Oct-4)	JJ	O
or	VBN	O
live	)	O
(SSEA-4,	CC	O
Tra	JJ	O
1-60	,	O
or	NNP	O
Tra	CD	O
1-81)	CC	O
cells	NNP	O
were	)	O
then	NNS	O
probed	VBD	O
for	RB	O
30	VBN	O
min	IN	O
at	CD	O
room	NN	O
temperature	IN	O
with	NN	O
a	NN	O
1:100	IN	O
dilution	DT	O
of	CD	O
the	NN	O
specific	IN	O
monoclonal	DT	O
antibody	JJ	O
or	JJ	O
an	NN	O
appropriate	CC	O
isotype	DT	O
control	JJ	O
antibody	NN	O
(Santa	NN	O
Cruz	NN	O
Biotechnology,	NNP	O
Inc.)	NNP	O
in	,	O
FACS	)	O
buffer	IN	O
(+0.1%	NNP	O
Triton-X100	NN	O
for	NN	O
fixed	NNP	O
cells).	IN	O
Cells	JJ	O
were	.	O
then	NNS	O
washed	VBD	O
and	RB	O
probed	VBN	O
in	CC	O
FACS	VBN	O
buffer	IN	O
(+0.5%	NNP	O
Triton-X100	NN	O
for	NN	O
fixed	NNP	O
cells)	IN	O
with	JJ	O
1:1000	)	O
dilution	IN	O
of	CD	O
an	NN	O
Alexaflour	IN	O
anti-mouse	DT	O
secondary	NNP	O
antibody	NN	O
(Invitrogen)	JJ	O
for	NN	O
30	)	O
min	IN	O
in	CD	O
the	NN	O
dark	IN	O
at	DT	O
room	NN	O
temperature.	IN	O
Cells	NN	O
with	.	O
the	NNS	O
EGFP-Oct-4	IN	O
knock-in	DT	O
construct	JJ	O
were	JJ	O
collected	NN	O
and	VBD	O
analyzed	VBN	O
directly.	CC	O
Cell	VBN	O
were	.	O
washed	NNP	O
in	VBD	O
FACS	VBN	O
Buffer,	IN	O
and	NNP	O
sorted	,	O
using	CC	O
a	VBD	O
FACSCalibur	VBG	O
flow	DT	O
cytometer	NNP	O
(Becton	NN	O
Dickinson).	NN	O
Acquisition	NNP	O
was	.	O
set	NNP	O
for	VBD	O
10,000	VBN	O
events	IN	O
per	CD	O
sample.	NNS	O
Dead	IN	O
cells	.	O
were	JJ	O
excluded	NNS	O
from	VBD	O
analysis	VBN	O
by	IN	O
staining	NN	O
with	IN	O
propidium	VBG	O
iodide	IN	O
(Invitrogen).	NN	O
Data	NN	O
were	.	O
analyzed	NNS	O
with	VBD	O
CellQuest	VBN	O
3.0	IN	O
software	NNP	O
(Becton	CD	O
Dickinson).	NN	O
All	NNP	O
treatments	.	O
were	DT	O
performed	NNS	O
in	VBD	O
duplicate.	VBN	O
Multiple	IN	O
replicates	.	O
were	JJ	O
performed	NNS	O
for	VBD	O
each	VBN	O
experiment.	IN	O
RT-PCR	DT	O
was	.	O
performed	NNP	O
with	VBD	O
previously	VBN	O
described	IN	O
gene-specific	RB	O
primers	VBN	O
on	JJ	O
100	NNS	O
ng	IN	O
of	CD	O
total	NN	O
RNA	IN	O
per	JJ	O
reaction	NNP	O
using	IN	O
an	NN	O
OneStep	VBG	O
RT-PCR	DT	O
Kit	NNP	O
(Qiagen)	JJ	O
following	NNP	O
manufacturer's	)	O
recommendations.	VBG	O
RNA	POS	O
concentrations	.	O
were	JJ	O
measured	NNS	O
by	VBD	O
UV	VBN	O
absorption	IN	O
with	NNP	O
a	NN	O
SmartSpec	IN	O
3000	DT	O
spectrophotometer	NNP	O
(Bio-Rad).	CD	O
H1	NN	O
cells	.	O
were	NNP	O
cultured	NNS	O
in	VBD	O
conditioned-medium	VBN	O
on	IN	O
Matrigel	NN	O
for	IN	O
32	NNP	O
passages,	IN	O
the	CD	O
WA15	,	O
and	DT	O
WA16	NNP	O
cells	CC	O
were	NNP	O
cultured	NNS	O
in	VBD	O
TeSR1	VBN	O
on	IN	O
human	NNP	O
matrix	IN	O
for	JJ	O
9	NN	O
and	IN	O
10	CD	O
passages	CC	O
respectively.	CD	O
Transcripts	NNS	O
were	.	O
visualized	NNS	O
on	VBD	O
ethidium	VBN	O
bromide	IN	O
stained	NN	O
agarose	NN	O
gels.	VBD	O
For	JJ	O
each	.	O
cell	IN	O
line,	DT	O
cytogenetic	NN	O
analysis	,	O
was	JJ	O
performed	NN	O
on	VBD	O
20	VBN	O
metaphase	IN	O
cells	CD	O
using	NN	O
G-banding.	NNS	O
For	VBG	O
long	.	O
term	IN	O
cell	JJ	O
cultures	NN	O
(H9,	NN	O
21	NNS	O
passages	,	O
in	CD	O
TeSR1)	NNS	O
and	IN	O
newly	)	O
derived	CC	O
cell	RB	O
lines	VBN	O
(WA15	NN	O
and	NNS	O
WA16,	NNP	O
10	CC	O
passages	,	O
in	CD	O
culture),	NNS	O
fluorescence	IN	O
in	,	O
situ	NN	O
hybridization	IN	O
(FISH)	JJ	O
was	NN	O
also	)	O
performed	VBD	O
on	RB	O
interphase	VBN	O
nuclei	IN	O
using	NN	O
probes	NN	O
specific	VBG	O
for	NNS	O
the	JJ	O
TEL	IN	O
gene	DT	O
on	NNP	O
chromosome	NN	O
12	IN	O
and	NN	O
the	CD	O
Her-2/neu	CC	O
gene	DT	O
on	NNP	O
chromosome	NN	O
17.	IN	O
Two	NN	O
hundred	.	O
cells	CD	O
were	JJ	O
examined	NNS	O
from	VBD	O
each	VBN	O
cell	IN	O
line.	DT	O
Trisomy	NN	O
12	.	O
and/or	$	O
17,	CD	O
commonly	NN	O
reported	,	O
in	RB	O
cultured	VBN	O
human	IN	O
ES	JJ	O
cells,	JJ	O
was	NNP	O
not	,	O
detected	VBD	O
in	RB	O
long	VBN	O
term	IN	O
cultures	JJ	O
of	NN	O
established	NNS	O
cell	IN	O
lines	VBN	O
or	NN	O
initial	NNS	O
(4	CC	O
months)	JJ	O
cultures	CD	O
of	)	O
newly	NNS	O
derived	IN	O
cell	RB	O
lines.	VBN	O
After	NN	O
four	.	O
months	IN	O
in	CD	O
culture,	NNS	O
WA16	IN	O
was	,	O
XXY	NNP	O
(Klinefelter	VBD	O
syndrome)	NNP	O
and	NNP	O
WA15	)	O
was	CC	O
karyotypically	NNP	O
normal	VBD	O
(XY;	RB	O
see	JJ	O
FIG.	:	O
14).	VB	O
Klinefelter	.	O
syndrome	.	O
is	NNP	O
the	NN	O
most	VBZ	O
common	DT	O
human	RBS	O
chromosomal	JJ	O
abnormality,	JJ	O
suggesting	JJ	O
that	,	O
this	VBG	O
abnormality	IN	O
may	DT	O
have	NN	O
been	MD	O
present	VB	O
in	VBN	O
the	JJ	O
embryo	IN	O
itself	DT	O
rather	NN	O
than	PRP	O
an	RB	O
artifact	IN	O
introduced	DT	O
by	NN	O
the	VBN	O
process	IN	O
of	DT	O
initiating	NN	O
the	IN	O
stem	VBG	O
cell	DT	O
culture.	NN	O
After	NN	O
7	.	O
months	IN	O
in	CD	O
culture,	NNS	O
WA16	IN	O
maintained	,	O
its	NNP	O
initial	VBD	O
karyotype,	PRP$	O
but	JJ	O
WA15	,	O
became	CC	O
trisomic	NNP	O
for	VBD	O
chromosome	JJ	O
12.	IN	O
In	NN	O
summary,	.	O
TeSR1	IN	O
containing	,	O
all	NNP	O
five	VBG	O
factors	DT	O
(bFGF,	CD	O
LiCl,	NNS	O
GABA,	,	O
PA	,	O
and	,	O
TGFβ)	NNP	O
is	CC	O
sufficient	)	O
to	VBZ	O
support	JJ	O
feeder-independent	TO	O
human	VB	O
pluripotent	JJ	O
stem	JJ	O
cell	NN	O
culture	NN	O
as	JJ	O
well	NN	O
as	RB	O
or	RB	O
better	IN	O
than	CC	O
fibroblast-conditioned	JJR	O
medium,	IN	O
and	JJ	O
remarkably,	,	O
these	CC	O
factors	,	O
do	DT	O
not	NNS	O
overlap	VBP	O
with	RB	O
the	VB	O
factors	IN	O
demonstrated	DT	O
to	NNS	O
sustain	VBD	O
mouse	TO	O
ES	VB	O
cells	NN	O
in	NNP	O
defined	NNS	O
conditions	IN	O
(Ying,	JJ	O
Q.	NNS	O
L.	,	O
et	NNP	O
al.	NNP	O
Cell	FW	O
115,	.	O
281-292	NNP	O
(2003)).	,	O
Three	CD	O
of	.	O
the	CD	O
factors	IN	O
present	DT	O
in	NNS	O
TeSR1	VBP	O
(bFGF,	IN	O
TGFβ	NNP	O
and	,	O
LiCl)	NNP	O
are	CC	O
believed	)	O
to	VBP	O
stimulate	VBN	O
signaling	TO	O
pathways	VB	O
previously	VBG	O
highlighted	NNS	O
in	RB	O
human	VBN	O
ES	IN	O
cell	JJ	O
culture	NNP	O
publications	NN	O
(see	NN	O
Xu,	NNS	B
C.	VB	I
et	,	I
al.	NNP	I
Stem	CC	I
Cells	.	I
23,	NNP	I
315-323	NNP	I
(2005);	,	I
Amit,	CD	B
M.	:	I
et	,	I
al.	NNP	I
J.	CC	I
Biol.	.	I
Reprod.	NNP	I
70,	.	I
837-845	.	I
(2004);	,	I
and	CD	O
Sato,	:	B
N.	CC	I
et	,	I
al.,	NNP	I
Nat.	FW	I
Med.	,	I
10,	.	I
55-63	.	I
(2004)).We	,	O
initially	CD	O
tested	.	O
GABA	PRP	O
because	RB	O
microarray	VBD	O
results	NNP	O
indicated	IN	O
increased	NN	O
expression	NNS	O
of	VBD	O
the	JJ	O
GABA-A	NN	O
receptor	IN	O
P-3	DT	O
subunit	NNP	O
by	NN	O
human	NNP	O
ES	NN	O
cells	IN	O
(see	JJ	O
Sperger,	NNP	B
J.	NNS	I
M.	VB	I
et	,	I
al.	NNP	I
Proc.	NNP	I
Natl.	FW	I
Acad.	.	I
Sci.	.	I
USA	.	I
100,	.	I
13350-13355	.	I
(2003)).GABA	NNP	O
is	,	O
an	CD	O
inhibitory	.	O
neurotransmitter	NNP	O
of	VBZ	O
the	DT	O
central	JJ	O
nervous	NN	O
system,	IN	O
and	DT	O
is	JJ	O
reported	JJ	O
to	,	O
stimulate	CC	O
proliferation	VBZ	O
of	VBN	O
both	TO	O
neural	VB	O
and	NN	O
non-neural	IN	O
tissues	DT	O
(see	JJ	O
Watanabe,	CC	B
M.,	JJ	I
et	NNS	I
al.	VB	I
Int.	,	I
Rev.	,	I
Cytol.	RB	I
213,	.	I
1-417	.	I
(2002)).We	.	O
tested	.	O
pipecolic	,	O
acid	CD	O
as	.	O
it	PRP	O
can	VBD	O
enhance	JJ	O
GABA-A	RB	O
receptor	IN	O
responses	PRP	O
(see	MD	O
Takahama,	VB	B
K.	NNP	I
et	NN	I
al.	NNS	I
Neuropharmacology	VB	I
25,	,	I
339-342	NNP	I
(1986)).Unlike	CC	O
previous	.	O
human	NNP	O
pluripotent	,	O
stem	CD	O
cell	.	O
culture	IN	O
media	JJ	O
that	JJ	O
included	NN	O
proprietary,	NN	O
poorly	NN	O
defined	NN	O
serum	NNS	O
components	WDT	O
with	VBD	O
undisclosed	,	O
formulations,	RB	O
all	VBN	O
TeSR1	JJ	O
components	NNS	O
are	IN	O
disclosed,	JJ	O
and	,	O
thus	DT	O
should	NNP	O
serve	NNS	O
as	VBP	O
a	,	O
starting	CC	O
point	RB	O
for	MD	O
further	VB	O
optimization	IN	O
by	DT	O
other	NN	O
investigators.	NN	O
One	IN	O
area	JJ	O
requiring	NN	O
improvement	IN	O
is	JJ	O
the	.	O
matrix,	CD	O
as	NN	O
the	VBG	O
purified	NN	O
human	VBZ	O
matrix	DT	O
components	,	O
are	IN	O
expensive	DT	O
and	JJ	O
provide	JJ	O
a	NN	O
potential	NNS	O
route	VBP	O
of	JJ	O
contamination	CC	O
by	VB	O
human	DT	O
pathogens.	JJ	O
Human	NN	O
serum	IN	O
albumin	NN	O
is	IN	O
the	JJ	O
only	.	O
component	NNP	O
in	NN	O
the	NN	O
TeSR1	VBZ	O
medium	DT	O
itself	JJ	O
that	NN	O
is	IN	O
not	DT	O
fully	NNP	O
defined,	NN	O
and	PRP	O
it	WDT	O
is	VBZ	O
possible	RB	O
that	RB	O
components	,	O
that	CC	O
co-purify	PRP	O
with	VBZ	O
it	JJ	O
influence	IN	O
human	NNS	O
pluripotent	IN	O
stem	NN	O
cells.	IN	O
Human	PRP	O
serum	NN	O
albumin	JJ	O
is	NN	O
routinely	NN	O
used	.	O
for	NNP	O
embryo	NN	O
culture	NN	O
during	VBZ	O
in	RB	O
vitro	VBN	O
fertilization	IN	O
procedures,	JJ	O
so	NN	O
its	IN	O
inclusion	IN	O
in	JJ	O
TeSR1	NN	O
does	,	O
not	IN	O
qualitatively	PRP$	O
change	NN	O
the	IN	O
risk	NNP	O
of	VBZ	O
introducing	RB	O
pathogens	RB	O
to	VBP	O
the	DT	O
pluripotent	NN	O
stem	IN	O
cells,	VBG	O
but	NNS	O
clearly	TO	O
the	DT	O
replacement	JJ	O
of	NN	O
this	,	O
component	CC	O
by	RB	O
cloned	DT	O
materials	NN	O
would	IN	O
be	DT	O
desirable.	NN	O
The	IN	O
new	JJ	O
human	NNS	O
ES	MD	O
cell	VB	O
line	.	O
WA15	DT	O
was	JJ	O
initially	JJ	O
normal,	NNP	O
but	NN	O
converted	NN	O
to	NNP	O
trisomy	VBD	O
12	RB	O
between	,	O
4	CC	O
and	VBD	O
7	TO	O
months	VB	O
of	CD	O
culture.	IN	O
The	CD	O
emergence	CC	O
of	CD	O
this	NNS	O
abnormal	IN	O
karyotype	.	O
could	DT	O
be	NN	O
associated	IN	O
with	DT	O
the	JJ	O
enzymatic	NN	O
dissociation	MD	O
used	VB	O
to	VBN	O
passage	IN	O
the	DT	O
cells.	JJ	O
Trisomy	NN	O
12	VBN	O
in	TO	O
human	VB	O
ES	DT	O
cells	.	O
has	$	O
been	CD	O
reported	IN	O
previously	JJ	O
(see	NNP	O
Draper,	NNS	B
J.	VBZ	I
S.	VBN	I
et	VBN	I
al.	RB	I
Nat.	VB	I
Biotechnol.	,	I
22,	NNP	I
53-54;	NNP	I
2004),